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Abstract 
The portal-drained viscera play a fundamental role m the supply of dietary 
nutrients to the rest of the body. On a tissue mass basis these organs consume a 
disproportionately higher quantity of dietary available nutrients. Of the portal-drained 
viscera, the intestine is unique, being able to utilize nutrients from both luminal and 
arterial sources. With regard to sulfur-containing amino acids, the small intestine 
consumes about 30% of dietary available methionine though the gastrointestinal system 
represents only about 7% of the whole body mass. This organ is known to contain all the 
necessary enzymes of transmethylation, remethylation and transsulfuration. 
Although the A-V balance of sulfur-containing amino acids across portal-drained 
viscera has been demonstrated by previous studies, the fluxes of sulfur-containing amino 
acids across the portal-drained viscera in the rat are not known. The fate of exogenous 
methionine within the enterocytes has not been elucidated. Therefore, in this thesis, the 
fluxes of major thiols across the portal-drained viscera and the metabolic fate of [l- 14C] 
methionine in isolated rat enterocytes were studied. Total cysteine was found to be 
exported to the portal blood in rats fed a 60% casein diet, a 20% casein supplemented 
with 0.6% cystine diet and a 20% casein supplemented with 0.5% methionine diet. The 
exported cysteine was entirely in the non-protein bound form in the portal plasma. 
Homocysteine was taken up from the arterial blood in rats fed a 2% methionine-
containing diet. Glutathione was taken up by portal venous-drained viscera in all diet 
groups except the 60% casein fed rats. 
11 
Exogenous labelled methionine was metabolized by enterocytes at approximately 
the same rate as in hepatocytes. However, there was no appreciable flux through the 
transmethylation pathway. Homocysteine was metabolized through the transsulfuration 
pathway into cysteine. These studies reveal an active sulphur-containing amino acid 
metabolism in the intestine. 
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CHAPTER! 
INTRODUCTION 
CHAPTER 1: INTRODUCTION 
1.1 METABOLISM OF SULFUR CONTAINING AMINO ACIDS 
The metabolism of sulfur-containing amino acids is shown in Figure- I. Since the 
other sulfur-containing amino acids are synthesized from methionine, methionine is the 
only essential (non-dispensable) sulfur-containing amino acid in mammals. The liver is 
thought to be the major organ of methionine metabolism and it contains all the enzymes 
shown in Figure- I. The foremost functions of the methionine cycle are to provide methyl 
groups for methylation reactions, to conserve the methionine carbon skeleton via 
remethylation and to catabolise excess methionine via the transsulfuration pathway. In 
addition, cysteine can be converted to glutathione and taurine. Alternative minor 
pathways also metabolize methionine. For example, methionine is transaminated to its 
keto acid, a-keto-y-methiolbutyrate. The other possible alternative pathways are 
polyamine synthesis and the cleavage of SAM into methylthioadenosine, which may be 
converted further, into methylthioribose and homoserine thiolactone. 
The methionine metabolic cycle comprises of two major arms: transmethylation 
and remethylation. In the transmethylation reactions, methionine is first converted into 
the high-energy sulfonium compound, S-adenosylmethionine (SAM). The next reaction 
is catalyzed by a large number of transmethylases by which the methyl group of SAM is 
transferred to any one of the large number of methyl acceptors. These enzymes bring 
about DNA, RNA and protein methylation, creatine synthesis and phosphotidylcholine 
synthesis. As a result, SAM is converted to S-adenosylhomocysteine (SAH), which is, 
then, reversibly hydrolysed to homocysteine (Hey) and adenosine. 
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Figure 1.1. The Transmethylation, Remethylation and Transsulfuration pathway. 
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Hey at this point can either be remethylated to methionine or irreversibly catabolized to 
cysteine (Cys) via the transsulfuration pathway. In the transsulfuration pathway, Hey is 
first condensed with serine to form cystathionine, which is then cleaved into Cys, a-
ketobutyrate and NH/. In the remethylation pathway, a methyl group is added to Hey 
moiety, which is thereby reconverted to methionine. The methyl group can arise from 
two possible sources. One is from N 5 -methyltetrahydrofolate (5-MTHF) and the other is 
from betaine. In the liver, both sources of methyl groups can be utilized for remethylation 
of Hey while in most extrahepatic tissues, only 5-MTHF can be utilized due to the 
absence of betaine: homocysteine methyltransferase (BHMT). 
Interest in methionine metabolism has been stimulated with the finding of a 
number of genetically determined defects as well as by demonstrating that elevated 
plasma total Hey is an independent risk factor for cardiovascular disease. 
METillONINE METABOLISM- TRANSMETHYLATION REACTIONS 
S-adenosylmethionine, a high-energy sulfonium compound, is the first product of 
the transmethylation pathway. The conversion of methionine into SAM is catalyzed by S-
adenosylmethionine synthase (SAM synthase; EC 2.5.1.6). The adenosyl moiety is 
transferred from adenosyl triphosphate (ATP) to the sulfur atom of L-methionine by this 
reaction (Cantoni 1953). In this reaction, ATP is completely dephosphorylated, which 
results in the formation of enzyme bound tripolyphosphate followed by an asymmetrical 
cleavage to inorganic phosphate and pyrophosphate. The reaction is physiologically 
irreversible. Three isozymes of SAM synthase have been found in mammals. The liver 
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specific and non-liver specific SAM synthases are products of two different genes (Chou 
2000). SAM synthase-! (a) is liver specific and shows half-maximal activity (Km) with an 
intermediate Km for methionine of 41 JJ,M (Hoffman et. al. 1979). It is slightly inhibited 
by the product, SAM and represents about 15% of total activity in the liver. SAM 
synthase-! is a tetramer of four identical subunits with a molecular weight of 208 000 
kDa. SAM synthase-II (y) is found in hepatic as well as extrahepatic tissues. 
Interestingly, this is the only isoform of SAM synthase found in fetal liver. It has the 
lowest Km for methionine and is strongly inhibited by SAM (Hoffman et. al. 1979). This 
kind of inhibition is extremely important, particularly in this enzyme reaction, because 
rapid synthesis of SAM would be fatal, perhaps as a consequence of A TP depletion 
(Karwick et. a/.1970). Five percent of total SAM synthase activity in the liver is brought 
about by this isozyme, which has a molecular weight of 120 000 kDa (Hoffman et. al. 
1979). Because of this low Km and the resulting high affinity of the y isoform for 
methionine, the velocity of SAM synthesis would be at its maximal in extrahepatic 
tissues. SAM synthase-Ill W) is also liver specific and has the highest Km value ranging 
from 0.3-1.3 mM for methionine (Finkelstein et. al. 1978). The high Km hepatic isozymes 
increase the production of SAM and thereby facilitate rapid clearance of excess dietary 
methionine available in the portal blood. Due to this tissue specificity and the different 
Km of SAM synthase for methionine, the tissue content of SAM is a function of both the 
organ concerned and the availability of methionine. For instance, the pool of SAM in the 
liver can increase to 650 nmoVg from the normal range of 50-100 nmol/g when the diet is 
supplemented with excess methionine (Finkelstein and Martin 1986). 
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SAM is at a key junction in methionine metabolism. It can undergo three possible 
metabolic fates, i.e. (i) transmethylation to SAH by transferring the methyl group to any 
one of the large number of methyl acceptors. SAM is considered as the methyl group 
donor for almost all the biological methylation reactions in mammals. There is one 
notable exception; it cannot act as a methyl group donor in the remethylation of Hey back 
into methionine (Stipanuk 1986). SAH is the spent form of transmethylated SAM. (ii) 
decarboxylation to 'decarboxylated SAM which is the aminopropyl group-donor for 
polyamine synthesis (Pegg et. al. 1998). (iii) cleavage of the linkage between carbon 4 
and the sulfur atom of the amino acid chain leading to the formation of 
methylthioadenosine and homoserine thiolactone (Swiatek et. al. 1973). Approximately 
two thirds of intravenously administered SAM is utilized by the combination of 
transmethylation and cleavage into methylthioadenosine plus homoserine in the rat 
(Giulidori et. al. 1984). However, the cleavage reaction uses only a minor quantity of 
SAM. Thus the bulk of SAM is used in transmethylation reactions. The rest is 
decarboxylated and used in the polyamine synthesis in rats (Giulidori et. al. 1984). Both 
the synthesis and metabolism of SAM via all of the above-mentioned mechanisms are 
ubiquitous reactions. 
In transmethylation reactions, the methyl group of SAM is transferred to a 
nitrogen, sulfur or oxygen atom in a wide range of methyl acceptor molecules. Among 
the products of this biological methylation, creatine, epinephrine, camitine, 
phospholipids, proteins, DNA and RNA are prominent. However, among these, the 
methylation of guanidinoacetate in creatine synthesis accounts for a greater consumption 
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of methyl groups than all other methylation reactions combined (Mudd and Poole. 1975; 
Giulidori et. a!. 1984). In addition, transmethylation reaction may be used as a means of 
degrading methyl groups (Stipanuk 1986). The methyl group of SAM can be degraded 
via the formation and oxidation of sarcosine (Mudd et. a!. 1980; Wagner 1982; Wittwer 
1981) (Figure-2). It has been found that the excess methyl groups available by means of 
methionine or choline are used in sarcosine synthesis, via the glycine methyltransferase 
reaction or the dimethylglycine dehydrogenase reaction (Mudd et. a!. 2001 ). Therefore, 
production and degradation of sarcosine play a major role in removing excess methyl 
groups (Mudd et. a!. 1980). 
Choline 
1 
Methionine Betaine 
~ Hey 
Methionine 
Dimethylglycine 
THF 
SAM 
I SAH 
Glycine __LL_____ Sarcosine 
THF S,10-CH2-THF THF 
\ ~Gl . ... " L .. s . ycme enne 
Figure 1.2. Pathway for methyl group oxidation 
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The co-product of all the SAM-dependent methyltransferase reactions is SAH which 
is then hydrolysed into adenosine and Hey (De La Haba and Cantoni 1959). This reaction 
is catalyzed by S-adenosylhomocysteine hydrolase (EC 3.3.1.1) and is the only 
physiologically reversible reaction in the pathway. This enzyme has a ubiquitous tissue 
distribution and contains a tightly bound NAD+, which is involved in the catalytic process 
(Elrod et. al. 2002; Kloor et. al. 2003). The disposal of SAH by this reaction eliminates 
undue product inhibition by SAH in most of the methyltransferases (Hoffman et. al. 
1979). Thus, the hydrolysis of SAH serves two purposes: maintaining the flux of 
methionine sulfur towards cysteine and playing a critical regulatory role in biological 
methylation (Hoffman, et. al. 1979). The molecular weight of the enzyme is 188 000 
kDa and it comprises of four identical subunits (Fujiolca and Takata 1981). The Km value 
for SAH is in the range of 8-60 J..LM while for Hey, it is about 160 J..LM (Finkelstein et. al. 
1978). The equilibrium constant of this reaction favours SAH synthesis. Therefore, for 
the forward reaction to occur, adenosine and Hey should be removed. Hey can be 
removed by two possible ways; either by remethylation to methionine or by 
transsulfuration to Cys (Eloranta et. al. 1984; 1982). Adenosine is removed by adenosine 
deaminase. Accumulation of SAH could occur when either Hey or adenosine 
accumulates, obstructing the hydrolytic reaction by mass action (Fox et. al. 1982). People 
with inherited defects in transsulfuration and remethylation pathways accumulate 
extremely high concentrations of SAH and SAM leading to interference with many of the 
biological methylation reactions. However, it appears that accumulation of intracellular 
SAH, which is present in free as well as protein-bound pools inside the cell, can be 
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reduced via a method independent of the hydrolase (Svardal and Ueland 1987). SAH is 
exported to the extracellular space when the cellular concentration is high (Hoffman et. 
al. 1980). 
1.2 TRANSSULFURATION 
Metabolism of Hey (2-amino-4-mercaptobutyric acid) is at a key junction of the 
methionine metabolic pathway and it links the methionine metabolic cycle with the folate 
metabolism. The metabolic fate of methionine depends on the route that Hey takes at this 
juncture, because transsulfuration is the only means of irreversibly dispensing 
methionine. Two pyridoxal-5'-phosphate (PLP) dependent enzymes, cystathionine-~­
synthase (CBS; EC 4.2.1.22) and cystathionine-y-lyase (CGL; EC.4.4.1.1) catalyze the 
transsulfuration of Hey to Cys. The final product of the transsulfuration pathway is Cys. 
Only very few organs, the liver, kidney, pancreas and small intestine, contain the 
capability of synthesizing Cys from methionine or Hey (Mudd et. al. 1965). Therefore, 
the synthesis of Cys from methionine and Hey is restricted to these tissues. Other tissues 
require an exogenous supply of Cys either from the diet or from any of those four organs. 
Thus, transsulfuration is essential not only as a way of elimination of excess Hey or 
methionine, but also, as a source of Cys and GSH. GSH may serve as a reservoir and a 
transport form of Cys. The initial and rate-limiting step of the transsulfuration pathway is 
catalyzed by CBS (Banerjee et. al. 2003). The irreversible nature of this reaction as well 
as the absence of an adequate source of Hey in the mammalian diet explains why 
methionine is a dietary essential amino acid (Sakamoto et. al. 2002). In this reaction, Hey 
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condenses with serine to form cystathionine. Cystathionine is an amino acid without a 
known function, other than as an intermediate in the biosynthesis of cysteine. CBS is 
unique in being dependent on two cofactors, PLP and heme. The presence of heme is 
required for PLP binding. Thus the amount of PLP bound is limited by the heme content 
(Kery et. al. 1994). Human CBS has a molecular weight of 63 kDa and exists as 
aggregates of tetramer of identical subunits (Taoka et. al. 1998). 
The distribution of Hey between the transsulfuration and remethylation pathways is 
nutritionally regulated. For example, when the diet contains a basal methionine level, 
Hey moieties are found to cycle through the methylation pathway about 1.5-2.0 times 
before they are catabolized through the transsulfuration pathway. When dietary 
methionine content is reduced by half, this cycling of Hey moiety increases twofold. 
Conversely, when the dietary methionine level is high, Hey cycling falls below basal 
levels (Eloranta et. al. 1990). This coordination is achieved by at least two mechanisms. 
One is the effect of SAM as an allosteric modulator of two enzymes in the remethylation 
and transsulfuration pathways. SAM allosterically inhibits methyltetrahydrofolate 
reductase, which catalyzes the formation of 5-MTHF, one of the two methyl donors for 
the remethylation of Hey to methionine (Finkelstein and Martin 1984a). SAM also 
activates SAM synthase. In patients with inherited SAM synthase deficiency a decreased 
activity of CBS is seen, possibly due to the lack of SAM mediated allosteric activation of 
CBS (Stabler et. al. 2002). The C-terminal domain of CBS is responsible for the SAM-
mediated allosteric activation of the enzyme. Human CBS contains anN-terminal heme 
(protoporphyrin IX) - containing domain and a catalytic domain in addition to the C-
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terminal domain. The catalytic domain binds to PLP (Taoka et. al. 1998). At the 
transcriptional level, hepatic CBS gene expression is hormonally regulated. Insulin is 
found to decrease the expression of the gene while glucagon and glucocorticoid 
hormones increase it (Jacobs et. al. 1998; Goss 1996; Jacobs et. al. 2001; Ratnam et. al. 
2002). The overexpression of CBS in children with Down's syndrome results in 
significantly reduced plasma levels of Hey, Met, SAH and SAM. Plasma cystathionine 
and cyst( e )ine are significantly increased in these patients (Finkelstein 2000). 
The intracellular concentration of SAM itself co-ordinates remethylation and 
transmethylation. Of the two SAM synthases in the liver, SAM synthase -I (a) has a 
higher affinity for methionine and is believed to function at normal physiological 
conditions (Hoffman et. al. 1979). SAM synthase -ill (f3) has the lowest affinity among 
all three SAM synthase isozymes for methionine, and is thought to function under 
conditions of high intake of methionine (Finkelstein et. al. 1978). Therefore, the changes 
in dietary methionine availability and the resulting intracellular methionine level, affects 
the rate of SAM synthesis, which in turn will determine the route the Hey moiety takes at 
the remethylation and the transsulfuration junction (Selhub 1999). 
Since Hey can be remethylated to methionine, CBS has to compete for the available 
Hey with the remethylation enzymes. A study using liver extracts and substrates at their 
in vivo concentrations has revealed that CBS has the lowest affinity for Hey when 
compared with methionine synthase and BHMT. On adaptation from a high protein to a 
low protein diet, the activity of CBS is reduced by 83%, which is equivalent to a 53% 
decrease in the Hey flux through transsulfuration. Therefore, this hierarchal access for 
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available Hey by the 3 enzymes is another way of regulation of the transsulfuration 
pathway (Finkelstein and Martin 1984a). In contrast to the diminished activity of CBS 
upon adaptation to a low protein diet, methionine supplementation in the diet increases 
the activity of CBS with a concomitant decrease in the hepatic levels of methionine 
synthase. An increase in the dietary methionine level from 0.3 to 3.0% causes the hepatic 
activity of CBS to increase by about 12-fold in rats. Simultaneously, the hepatic content 
of serine is decreased when the dietary methionine level is increased above 0.3% 
(Finkelstein and Martin 1986). This is due to the higher demand for serine to be 
condensed with Hey in the transsulfuration pathway. 
Although Cys is not a precursor of methionine, the supplementation of Cys in the diet 
can replace the dietary requirement in humans for methionine by more than half (Di 
Buono et. a!. 2003). In the rat, the supplementation of 0.8% of Cys in the diet results in a 
significant decrease in SAM and a two-fold increase in the serine content. The outcome is 
a 70% sparing of the dietary requirement for methionine (Finkelstein et. a!. 1988). The 
enzymatic basis for this phenomenon is the marked decrease in hepatic CBS due to the 
low SAM level and the resulting absence of a potent allosteric stimulus on the CBS 
enzyme (Di Buono et. a!. 2001 ). This is consistent with the early findings of in vivo 
studies in rats fed a low methionine diet with added Cys to meet the sulfur amino acid 
requirement. The liver CBS activity was diminished in these animals (Finkelstein and 
Mudd 1967). 
CGL catalyzes the fmal step of the transsulfuration pathway where cystathionine is 
converted to Cys. In addition, homoserine deamination and the desulfhydration of Cys 
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are also catalyzed by this enzyme (Pascal et. al. 1972; Yao et. al. 1979). CGL is a PLP-
dependent enzyme which catalyses the ~-cleavage of cystathionine. Its molecular weight 
is 160 000-210 000 k.Da for the rat liver enzyme and 190 000 k.Da for the human 
lymphoid enzyme (Matsuo and Greenberg 1959). The rat liver enzyme has a Km value for 
cystathionine of 3 mM (Finkelstein 2000). The products of this reaction are Cys, a-
ketobutyrate and NH3. Cysteine has a number of different metabolic fates, depending on 
the tissue. These include incorporation into proteins as well as glutathione (GSH) and 
synthesis of taurine. These fates are discussed under the section of cysteine metabolism. 
1.3 REMETHYLATION 
Hey can be remethylated to methionine via two different means. By remethylation, 
the carbon skeleton of an essential amino acid is conserved. Remethylation may occur via 
methionine synthase (E.C.2.1.1.13), which has a ubiquitous distribution in mammalian 
tissues (Finkelstein et. al. 1971 and Xue 1985). This enzyme is the focus that connects 
methionine, vitamin B12 and folate metabolism. The mammalian enzyme contains tightly 
bound vitamin B 12 as the prosthetic group. It is methylated by the folate substrate. 
Methionine is generated as a result of the methyl group transfer from methylated 
cobalamin to Hey. A catalytic amount of SAM is needed for the initial priming of 
enzyme bound cobalamin. Methionine synthase is one of the two enzymes, identified so 
far, to require cobalamin as a cofactor, the other being methylmalonyl -CoA mutase that 
catalyzes the conversion of methylmalonyl-CoA into succinyl-CoA (Burke et. al. 1971; 
Cantoni et. al. 1982). Methionine synthase has a Km value of 60 J.LM for Hey (Finkelstein 
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1974). The methyl group donor in this reaction is 5-MTHF. This is the only reaction 
known in mammalian tissues involving 5-MTHF. Thus, the folate cycle is highly 
dependent upon the methionine synthase reaction to generate free tetrahydrofolate (THF) 
from its methylated form. 
Deficiency of vitamin B 12 possibly results in an accumulation of intracellular 5-
MTHF at the expense of other forms of folate such as pteroic acid, dihydrofolic acid etc 
(Vidal and Stokstad1974). This is known as the methyl trap. 5-MTHF cannot be 
reoxidized to methylenetetrahydrofolate, because this reaction is essentially irreversible 
under physiological conditions (Kutzbach et. al. 1971 ). Under physiological conditions, it 
appears that the action of SAM inhibits MTHFR (EC. 1.1.99.15) which tends to minimize 
the trapping of 5-MTHF (Daubner et. al. 1982). 
Methionine synthase is not the only means for the remethylation of Hey into 
methionine (Finkelstein et. al. 1982a). A second route is via the reaction catalyzed by 
BHMT (E.C. 2.1.1.5). This is a zinc metalloenzyme (Breksa et. al. 1999; Evans et. al. 
2002). Unlike methionine synthase, BHMT has more limited tissue distribution with a 
significant activity found only in the rat liver (Finkelstein et. al. 1971 ). In humans a 
significant BHMT activity is found in the liver, kidney and eye lens. In sheep, this 
enzyme is active in a number of tissues such as kidney, liver, adrenal and pancreas, 
which, surprisingly, accounts for the highest activity (Xue G.P et. al. 1985). 
The reported Km values of the rat liver BHMT are 15-21 J..LM and 49-56 J..LM for Hey 
and betaine, respectively (Finkelstein et. al. 1971, Skiba et. al. 1982). Betaine, an 
obligatory intermediate in the choline catabolism, is the methyl group donor in this 
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reaction. BHMT activity is inhibited in vitro by SAM (Finkelstein and Martinl984b). In 
rats fed a high protein diet, liver BHMT activity is increased (Finkelstein et. al. 1971). 
The response of BHMT to methionine in the diet is biphasic; the supplementation of a 
low (0.3%) level of methionine to a methionine-free diet in rats causes a significant 
decrease in the enzyme activity. In contrast, the addition of 1% methionine to the diet 
results in a marked increase in rat liver BHMT activity. Conversely, when the diet is 
deficient in methionine, BHMT activity is increased and at this situation BHMT takes 
part in methionine conservation (Finkelstein 1982b ). 
1.4 POLYAMINE SYNTHETIC PATHWAY 
Polyamines are ubiquitous constituents of mammalian tissues and hence, the 
biosynthesis of polyamines is an important pathway of SAM utilization particularly in 
organs with rapid proliferating cells. In vivo studies in rats intravenously injected with 
differentially labelled SAM, reveal that 10-30% of exogenous SAM is metabolized by the 
polyamine synthetic pathway (Giulidori et. al. 1984). Po1yamines are aliphatic organic 
cations with important physiological roles in cell growth and proliferation. 
Decarboxylated S-adenosylmethionine ( dSAM) is the source of the aminopropyl group 
for polyamine synthesis (Pegg et. al. 1998). No other reaction that utilizes dSAM at 
physiologically significant rates is known. Adenosylmethionine decarboxylase is the 
enzyme responsible for the decarboxylation of the carboxyl carbon of SAM in mammals 
(Pegg et. al. 1969). 
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The tissue availability of SAM is believed to be one of the regulators of the rate of 
polyamine synthesis. The tissue content of dSAM ranges from 0.9 to 2.5 nmollg wet 
weight which is 2-5% of that of SAM (Hibasami et. al. 1980b ). In addition to methionine, 
argmme is also required for the de novo synthesis of polyamines. Arginase converts 
argmme to ornithine. Then, ornithine is decarboxylated to putrescine in a reaction 
catalyzed by ornithine decarboxylase. The active aminopropyl group of dSAM that 
contains the carbon atoms 3 and 4 of the original methionine molecule is then transferred 
to putrescine which results in the formation of polyamines and 5-methylthioadenosine 
(MTA) by a reaction catalyzed by spermidine/spermine synthase (Heby and Persson 
1990). As illustrated in Figure 1.3, methionine channelled into this pathway is not 
wasted; instead it is salvaged by the conversion of MT A through methylthioribose into 
methionine. The methionine salvage pathway has two physiologically important 
functions; as a method of conservation of adenosine and methionine and most 
importantly, it removes MTA which is a strong inhibitor of aminopropyl transferase of 
polyamine biosynthesis (Hibasami et. al. 1980a; Pegg et. al. 1981 a and 1981 b). 
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Figure 1.3. Polyamine pathway 
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1.5 TRANSAMINATION 
Benevenga and coworkers have suggested an alternative pathway for methionine 
metabolism (Figure 1.4). This involves transamination of methionine to a-keto-y-
methiolbutyrate as the initial step (Case and Benevenga 1976; Steele and Benevenga 
1978). The presence of the amino-accepting keto acid, a-keto-y-methiobutyrate, has 
resulted in an increase in C02 production from the carboxyl carbon of methionine during 
in vitro studies (Benevenga and Eagen 1983). This reaction has been detected in liver, 
kidney, heart, brain, spleen, skeletal muscles and small intestinal homogenates of rats. 
The keto acid is decarboxylated within the mitochondria resulting in the formation of 3-
methylthiopropionate (Dixon and Benevenga 1980; Livesey and Lund 1980). Further 
metabolism of this product gives rise to methenethiol, H2S, sulfate, C02, formaldehyde 
and formate (Cohen and Benevenga 1985). The methyl carbon of 3-methylthiopropionate 
has been observed to be oxidized to C02 in liver and kidney homogenates (Steele and 
Benevenga 1979). However, the occurrence of this pathway in intact animals is not well 
established. SAM is neither a substrate nor an inhibitor of methionine transamination in 
liver homogenates (Case and Benevenga 1976). 
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Figure 1.4. Methionine transamination pathway 
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1.6 CLEAVAGE OF SAM INTO METHYLTIDOADENOSINE 
Cleavage of SAM into methylthioadenosine and homoserine thiolactone is another 
fate of this nucleotide. SAM is cleaved at the linkage between carbon 4 and the sulfur 
atom in the amino acid chain, leading to the formation of methylthioadenosine and 
homoserine thiolactone (Swiatek et. al. 1973). The utilization of SAM in this reaction 
was first identified in cell-free extracts of Aerobacter aerogenes and in Escherichia coli 
infected with bacteriophage T3 (Shapiro and Mather 1958; Gefter et. al. 1965). Later, it 
was found to occur in mammalian tissues as well (Swiatek et. al. 1973). In rats, this 
pathway together with transmethylation pathway is responsible for the utilization of two 
thirds of the intravenously administered labelled SAM (Giulidori et. al. 1984). However, 
it does not necessarily mean that cleavage of SAM to homoserine is responsible for the 
utilization of a significant amount of SAM. The physiologic significance of this pathway 
is still not clear as there are no strong data to show the synthesis of homoserine from 
SAM under normal physiological conditions. The ability of cells to take up intravenously 
administered SAM is not clear. Hoffman et. al. (1980) claimed that the perfused liver is 
impermeable to SAM. Nevertheless, experiments cited above show the metabolism of 
intravenously administered SAM. As shown in Figure 1.5, methylthioadenosine can be 
reconverted to methionine, while homoserine thiolactone is catabolized via a-keto-
butyrate to propionyl CoA. The carboxyl carbon atom of homoserine, which comes from 
methionine, is decarboxylated at this step. Further degradation of propionate releases the 
methyl carbon atom 3 as C02• a-keto-butyrate produced from the y cleavage of 
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Figure 1.5. Cleavage of SAM at the linkage between carbon 4 and the sulfur atom in 
the amino acid chain, leading to the formation of methylthioadenosine and homoserine 
thiolactone 
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cystathionine in the transsulfuration pathway also shares the same catabolic pathway with 
homoserine (Giulidori et. al. 1984). 
1.7 METABOLISM OF CYSTEINE 
The major fates of Cys, which is derived from the transsulfuration pathway or 
provided from dietary sources, include incorporation into proteins and utilization as a 
precursor in the synthesis of the tripeptide GSH and the synthesis and catabolism of 
taurine. Among the critical functions of these metabolic products of Cys, synthetic 
reactions, osmotic regulation, antioxidative function, detoxification and involvement in 
nervous system functions are prominent. Cys present in excess is associated with some 
cytotoxic and neurotoxic effects (Montine et. al. 1997 and Reis et. al. 2000). Elevated 
plasma Cys was recently suggested to be an independent risk factor for cardiovascular 
disease (El-Khairy et. al. 2001). 
As shown in the Figure 1.6 Cys is mainly catabolized v1a cysteinesulfinate-
dependent pathways (Yamaguchi et. al. 1973; Griffith 1983). Cys in this pathway, is 
utilized either as a precursor for taurine synthesis or as a substrate for pyruvate and 
inorganic sulfate production (Stipanuk and Rotter 1984). Intake of a high protein diet is 
associated with metabolic acidosis, which is largely attributed to the degradation of the 
sulfur amino acids to yield sulfonic acid (Lemann et. al., 1959 and Trilok et. al., 1989). 
Therefore, in the cysteinesulfmate-dependent pathway, the distribution of Cys catabolism 
between taurine synthesis and the complete catabolism into sulphate products has 
implications for the acid-base homeostasis (Bella and Stipanuk 1995). 
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Cysteine dioxygenase (CDO; EC.1.13.11.20) catalyzes a key regulatory step in the 
conversion of Cys into cysteinesulfinate. This is an Fe2+ metalloenzyme and has a Km of 
0.45 mM for Cys. In this reaction, CDO adds molecular oxygen to the thiol group of 
cysteine to synthesize cysteinesulfinate. Thus, the sulfhydryl group is oxidized 
(Yamaguchi et. al. 1978). The hepatic activity of CDO in the rat liver is highly sensitive 
to the dietary protein and SAA level. The increase in dietary casein or SAA causes a 
rapid rise in rat liver CDO activity (Bella et. al. 1999b; Lee et. al. 2004). The rat liver 
CDO activity is found to increase 7-fold when the protein content of the diet is increased 
from 10% to 60o/o casein. Further, the supplementation of 0.3% and 1% L-methionine in 
the diet results in 2.8 and 13-fold increase in the CDO activity in the rat liver, 
respectively (Stipanuk et. al. 1994). The activity of CDO does not change in response to 
supplemental non-sulfur amino acids alone (Bella et. al. 1999a). 
y-Glutamylcysteine Synthase (GCS; EC. 6.3.2.2) which catalyzes the key reaction 
in GSH synthetic pathway competes with CDO for the available cysteine. GCS also 
responds to the sulfur amino acid and protein availability in the diet. Rat liver GCS 
activity, GCS-HS (catalytic/ heavy subunit) protein level and GCS mRNA concentration 
are lowered as a result of high casein or methionine supplementation (Bagley and 
Stipanuk 1994 and 1995; Lea et. al. 2004). There are also alternative, cysteinesulfinate-
independent and cyst( e )ine desulfhydration, pathways which make some contribution to 
Cys catabolism (Drake et. al. 1987). The enzymatic catabolism by the latter two 
pathways include the cleavage of cyst( e )ine by y-cystathionase and the transamination of 
cysteine to form 3-mercaptopyruvate (Stipanuk and Beck 1982; Drake et. al. 1987). 
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Figure 1.6. Pathways of cysteine metabolism 
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1.8 INTESTINAL METABOLISM OF SAA 
The liver is thought to be the major site of methionine metabolism; hence most of 
the previous studies have focused on this tissue. Most studies of SAA metabolism in 
intestinal tissues are related to the metabolism of Cys. Studies on intestinal metabolism of 
methionine are lacking. Even though the liver is considered to be the major organ 
responsible for methionine metabolism, about 30% of dietary available methionine is 
sequestered in the portal-drained viscera (PDV) in the first pass metabolism in piglets 
(Reeds et. al. 1996). This is all the more remarkable, since the PDV represents only about 
7% of the total body mass. However, among the very few organs which contain all the 
enzymes of methionine metabolic pathway except BHMT, the rat small intestine has the 
least capacity for transsulfuration. (Mudd et. al. 1965). 
Methionine and Cys are consumed in dietary proteins. The estimated requirement 
of these two sulfur amino acids for an adult human is 15 mg/kg/day (Di Buono et. al. 
2001; Storch et. al. 1988). The average intakes of methionine and cysteine in the United 
States are 2.3 and 1.3 g/day for men and 1.6 and 0.9 g/day for women (Stipanuk 2004). 
Thus, the daily intake is well above the requirement. The transport of dietary methionine 
into the intestinal mucosa is carried out by neutral amino acid transport systems such as 
B0 '+, ASC and L (Segawa et. al. 1999). Also, a fraction of dietary methionine is 
transported in peptide form by peptide transport systems (Matthews et. al. 1969). The 
intestinal absorption of dietary Cys is Na+ dependent (Segawa et. al. 1999). Neutral 
amino acid transporters, including system B and ASC, absorbs Cys in this way (Stipanuk 
2004). 
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In vitro studies reveal that Cys is catabolized into pyruvate and sulfate products 
within the enterocytes (Coloso et. a/. 1989). However, Cys or cysteinesulfmate is not 
utilized for taurine synthesis in these cells (Coloso et. al. 1989). Half of Cys metabolism 
occurs via cysteinesulfinate-dependent pathway, which includes a transamination 
reaction catalyzed by aspartate aminotransferase. The other half is oxidized via 
cysteinesulfinate-independent desulfhydration pathways, mainly one that involves the ~­
cleavage of cystine by y-cystathionase. The metabolic product, pyruvate, is further 
catabolized to C02 within the enterocytes. The catabolism of Cys to C02 within the 
enterocytes is substantial when compared with that ofhepatocytes (Coloso et. a/. 1989). 
1.9 REDOX STATUS AND PROTEIN BINDING OF TIDOLS IN THE PLASMA 
The major aminothiols in plasma include Hey, Cys, Cys-Gly and GSH. They exist 
m different forms in plasma. The sulfhydryl group has an ability to oxidize in the 
presence of an electron acceptor such as molecular oxygen. This kind of autooxidation 
results in the formation of disulfide bonds between the same type of thiol molecules or 
with another thiol. Thus, Hey, Cys and GSH will autooxidize into their oxidized forms; 
homocystine, cystine and oxidized GSH (GSSG), respectively. Thiols oxidized with 
another thiol results in the formation of mixed disulfides such as the homocysteine-
cysteine mixed disulfide and the homocysteine-glutathione mixed disulfide. The rate of 
autooxidation of thiols depends on several factors. Among them the copper-binding 
plasma protein, ceruloplasmin, and albumin are important (Fedman et. a/. 1982; Sengupta 
et. al. 2001a). The copper ion attached to ceruloplasmin is responsible for the 
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autooxidation of L-Cysteine, Cys-Gly and GSH. However, neither ceruloplasmin nor 
copper ion bound to ceruloplasmin is a significant physiological catalyst for the 
autooxidation of L-Homocysteine. The autooxidation of Hey in plasma is mainly 
mediated by albumin by thiol:disulfide exchange reaction. Copper attached to albumin is 
responsible for only about 20% of the total autooxidation of Hey (Sengupta et. al. 2001a). 
In spite of the free reduced and free oxidized thiols, the bulk of Hey and Cys 
present in human plasma is bound to plasma proteins (Peters 1996). In healthy 
individuals, the free reduced Hey in the circulation is less than 1% of the total value 
which is about 10 )lmol/L. The free oxidized fraction is about 30% and the predominant 
form, the plasma protein-bound fraction is almost 70%. Cys is the most abundant type of 
all aminothiols at a total concentration of about 250 )lmol/L in human plasma. About 
65% of this is in the albumin-bound form and of the rest, 3-4% is in the free reduced 
form (Mansoor et. a/. 1993). However, in rat plasma, about 60% of plasma total Cys is in 
the free form; not bound to albumin (Maloy et. al. 1981). The plasma total Cys-Gly 
concentration in humans is about 30 )lmol/L and of it 17 )lmol/L is bound to plasma 
proteins (Mansoor et. al. 1993). The free reduced fraction is about 10% (Mansoor et. a/. 
1993). GSH is the least abundant thiol in the human plasma, with a concentration of 
about 6 )lmol/L. More than 80% of GSH in human plasma is in the free reduced form. 
The protein-bound fraction represents only about 25% of the total (Mansoor et. al. 1993). 
Albumin is the most abundant protein in plasma. In humans total plasma albumin 
concentration ranges from 0.6 to 0.75 mM (40-45 g/L). This represents more than 50% of 
total plasma protein level in humans (Curry et. al. 1998). In young rats, the plasma 
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albumin concentration is reported to be 33 giL (Peters 1996). Albumin is the predominant 
Hey-binding protein in human plasma. More than 90% of total bound Hey in the plasma 
is bound to albumin (Sengupta et. al. 2001b). The fraction of protein-bound Hey 
increases as a function of total plasma Hey up to a maximal binding of 140 J..LmoVL in 
humans. This may represent the saturation of all the available Hey-binding sites in 
plasma albumin. Cys is displaced and thereby the albumin-bound Cys is decreased in 
these situations, equivalent to the increase in Hey binding (Ueland et. a!. 1996). 
Albumin is a nonglycosylated, single-chain polypeptide that is synthesized 
exclusively by the liver. Formation of 17 intra-chain disulfide bonds between 34 of the 
total of 35 Cys residues defines the fmal structure of the tightly folded three domain 
structure of albumin. One Cys residue at Cys34 is left unbound as a result of this intra-
chain disulfide bonding. This free Cys34 residue accounts for the bulk of bound thiols (-
SH) in plasma (Peters 1996). Thus, one third of the albumin molecules in the plasma are 
disulfide-bonded with plasma thiols (Carter et. a!. 1994). Once synthesized in the liver, 
albumin is secreted into the circulation in the free thiolate anion form (Peters 1996); this 
highly reactive thiolate anion is able to make disulfide bonds with plasma thiols at 
physiological pH (Carteret. al. 1994). 
According to a model proposed by Christoduolou et. a!. (1994 and 1995) Cys34 exists 
in two forms; one in exposed and the other in the buried form. In the buried form Cys34 is 
in close proximity to His39, making a stable salt bridge. The exposed form is stabilized 
with the formation of a disulfide bond with Hey or Cys. In vitro studies using human 
serum albumin reveal that Hey displaces Cys from albumin. Nevertheless, 
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stoichiometrically, the formation of new albumin-bound Hey does not equal the Cys 
released from albumin. Instead, a higher amount of Cys is released in response to a 
formation of a lesser amount of albumin-bound Hey (Togawa et. a!. 2000). The reason 
for this difference is believed to be the formation of albumin thiolactone anion (Sengupta 
et. a!. 2001 b). The bulk of the Hey added and as well as the Cys which is released from 
albumin-bound form then undergo autooxidation; homocystine, cystine and 
homocysteine-cysteine mixed disulfide are formed (Sengupta et. a!. 2001 b). 
According to a model proposed recently by Sengupta et. a!. (2001a), L-cysteine in 
human plasma is oxidized into cystine by ceruloplasmin. Nascent albumin thiolate anion 
released from the liver into the circulation attacks L-cystine to form albumin-Cys34 -S-S-
cysteine. L-homocysteine then reacts with this Cys-bound albumin, which results in the 
formation of the homocysteine-cysteine mixed disulfide. Albumin then returns to its 
thiolate anion form, which can then attack the homocysteine-cysteine mixed disulfide. As 
a result, albumin-Cys34 -S-S-homocysteine and the cysteine thiolate anion are formed. The 
autooxidation of L-homocysteine is catalyzed by copper co-ordinated to His3 of albumin 
but not by ceruloplasmin. Albumin thiolate anion can react with this homocystine to 
make some additional albumin-Cys34-S-S-homocysteine (Sengupta et. a!. 2001a). In the 
measurement of total plasma Hey or Cys, the protein-bound fraction is reduced to the free 
form by a suitable reducing agent. However, it does not include thiols bound to protein 
by an amide linkage, such as compounds formed by the reaction of homocysteine 
thiolactone with the lysine residues of protein (Jakubowski 1999). 
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1.10 HYPERHOMOCYSTEINEMIA 
1.10.1 Hyperhomocysteinemia and cardiovascular disease risk 
Thirty years after the discovery of homocysteine by du Vigneaud, the fust case of 
a congenital anomaly associated with homocysteine was found. It was observed in 
mentally challenged children who had a high level of Hey in blood as well as urine 
(Carson and Neil 1962; Gerritsen et. a/. 1964). From then, numerous vascular lesions 
were found in patients with hyperhomocysteinemia (McCully 1969; Kanware et. a/. 
1976), which led McCully and Wilson (1975) to postulate that hyperhomocysteinemia 
predisposes to atherosclerosis. Hyperhomocysteinemia can result from either increased 
production or decreased removal of Hey. A number of factors such as inborn errors in 
methionine metabolic enzymes, deficiencies of various B vitamins which play important 
roles as cofactors in this cycle, chronic renal failure and certain chemotherapeutic agents 
are responsible for decreased rate of removal of plasma Hey (Kang 1996; Selhub 1999). 
The most common cause of severe homocysteinemia and consequential 
homocystinuria in humans is inborn errors in CBS. Inadequate CBS activity is known to 
cause Hey accumulation and its consequential export from the cell, leading to 
hyperhomocysteinemia (Pogribna et. a/. 2001). This was shown in CBS knockout mice; 
plasma Hey levels were about 40 times higher than normal in the homozygous mice and 
2 times higher than normal in heterozygous mutants (Watanabe et. a/. 1995). Vitamin B6 
deficiency is another common cause of hyperhomocysteinemia since both CBS and CGL 
are PLP- dependent enzymes (Cuskelly et. a/. 2001; Guttormsen et. a/. 1996). The second 
most common cause of hyperhomocysteinemia is decreased remethylation due to inborn 
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defects in N5•10 methylene-tetrahydrofolate reductase activity (Poole et. al. 1975). Inborn 
errors affecting methionine synthase and various steps in the synthesis of 
methylcobalamin, which is an essential cofactor for this enzyme, also are among the 
causes for hyperhomocysteinemia. In addition, vitamin B 12 and folate deficiency result in 
hyperhomocysteinemia (Guttormsen et. al. 1996; Kluijtmans et. al. 2003). 
Urinary excretion is not a significant route of removing Hey, as only a very 
limited amount of extracellular Hey is excreted via this route. About 1-2% (3.5 - 9.8 
J.lmol/day) of Hey in the glomerular filtrate is excreted (Refsum et. al. 1985; Svardal et. 
al. 1986). The bulk is reabsorbed by renal cortical tubules via a high affinity system 
shared with cystine and dibasic amino acids (Foreman et. al. 1982). However, plasma 
total Hey is quite elevated in patients with renal failure. This level rises steeply when the 
patient develops terminal uremia (Chauveau et. al. 1996). 
Hey metabolism can be affected by certain chemotherapeutic agents such as 
theophylline, carbamazepine and valproate. Theophylline is a vitamin B6 antagonist 
whereas valproate has antifolate effects. Therefore, hyperhomocysteinemia resulting from 
these drugs is secondary to vitamin deficiencies (Karabiber et. al. 2003). 
10.1.2 Hyperhomocysteinemia associated with intestinal diseases 
Hyperhomocysteinemia and venous thrombosis are found m patients with 
Inflammatory Bowel Disease (IBD) and Short Bowel Syndrome (SBS). Since these 
patients require long term indwelling catheters because of the requirement for parenteral 
feeding, it was earlier believed that the venous thrombosis is developed secondary to the 
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usage of intravenous catheters. However, it is now established that venous thrombosis in 
these patients is due to hyperhomocysteinemia (Cattaneo et. a/. 1998; Compher et. al. 
2000; Oldenburg et. a/. 2000). 
Hyperhomocysteinemia associated with SBS is usually related to vitamin B 12 
deficiency (Compher et. al. 2000). However, in ffiD patients, it is not necessarily related 
to a deficiency of vitamin B 12 though these patients have low levels of vitamin B 12 
(Romagnuolo et. al. 2001; Koutroubakis et. al. 2000). The elevation of tHey in ffiD and 
SBS patients is minor (from 10.5 ~-tmol/L to 12.2 ~-tmol/L) when compared that with 
severe hyperhomocysteinemia in patients with inherited defects in methionine metabolic 
enzymes. 
Bakker et. al. (1997) reported on a patient with ulcerations of the stomach and the 
small intestine who had a substantially higher plasma tHey level than normal. In addition, 
this patient had atherosclerotic lesions in the mesenteric artery (Bakker et. al. 1997). 
According to another case report, acute thrombosis was found in the superior mesenteric 
artery of a patient who had previously undergone bowel resection surgery. Further, the 
same patient had a markedly elevated level of plasma tHey (Gradman et. al. 2001). A 
cross-sectional study carried out by Romagnuolo et. al. (200 1 ), showed that 
hyperhomocysteinemia is significantly more common in patients with mn than in the 
normal population. Though these patients have some lower values for vitamin B12, they 
are not necessarily deficient in it (Romagnuolo et. al. 2001 ). 
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CHAPTER2 
MATERIALS AND METHODS 
MATERIALS 
Animals and Diets 
Male Sprague-Dawley rats weighing 200-300 g were used for all experiments. 
Rats were obtained from Memorial University's breeding colony and were housed and 
treated in accordance with the guidelines of the Canadian Council on Animal Care 
(1993). The university's Institutional Animal Care Committee approved all procedures. 
The rats were housed, two in a cage, at 22 ± 2 °C, with free access to tap water and 
commercial rat chow (Prolab® RHM 3000). The feeding conditions during the diet 
experiments will be described in the section of experimental protocol. 
Chemicals 
All chemicals used in these experiments were of analytical grade. Sodium 
pentabarbitol was obtained from MTC Pharmaceuticals (Cambridge, Ontario, Canada). 
Ammonium-7-fluorobenzo-2-oxo-1,3-diazole-4-sulphonate was purchased from 
Molecular Probes (Eugene, Oregon, USA). Sodium heparin was from Solopak 
Laboratories Inc. (Elk Grove Village, Illinois, USA). All the diet constituents were 
purchased from ICN Biomedicals Inc. (Aurora, Ohio, USA). Tri-n-butylphosphine was 
obtained from Acros (New Jersey, USA). All other chemicals and amino acids used in 
this study were obtained from Sigma Chemical Co. (St. Louis, MO) unless otherwise 
noted. 
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Radioisotopes 
All radioisotopes were purchased from American Radiolabelled Chemicals Ltd., 
(St. Louis, MO, USA) 
METHODS 
1). Net Fluxes of Thiols and Amino Acids across the Portal-Drained Viscera in Rats 
Fed Different Diets 
Feed Ingredients 
A modified AIN 93G diet, designed to meet the nutritional requirements for the 
growth of laboratory rats, was used. The six diet groups were different from each other in 
the content of casein, cystine and methionine. A control group of 20% casein with 0.3% 
cystine (D 1) was tested against the rest of the diet groups: 20% Casein + 0.6% cystine 
(D2), 60% Casein + 0.3% cystine (D3), 20% Casein + 0.3% cystine + 0.5% methionine 
(D4), 20% Casein+ 0.3% cystine+ 1% methionine (D5) and 20% Casein+ 0.3% cystine 
+ 2% methionine (D6). The composition ofthe diet is given in Table 2.1. 
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Table 2.1. Composition of purified diets 
Ingredient 20% + 20% 60% 20% 20% 20% 
Casein Casein+ Casein Casein+ Casein+ Casein+ 
+0.3% 0.6o/o +0.3% 0.3% 0.3% 0.3% 
cystine cystine cystine cystine cystine cystine 
diet diet diet +0.5% +1% +2%Met 
(Dt) (D2) (DJ) Met (D4) Met (Ds) (D6) 
Cornstarch 397.486 394.486 144.486 392.486 387.486 377.486 
Casein 200.00 200.00 600.00 200.00 200.00 200.00 
Dextrinized 132.00 132.00 48.00 132.00 132.00 132.00 
cornstarch 
Sucrose 100.00 100.00 37.00 100.00 100.00 100.00 
Soybean oil 70.00 70.00 70.00 70.00 70.00 70.00 
Alphacel 50.00 50.00 50.00 50.00 50.00 50.00 
AIN-93G mineral 35.00 35.00 35.00 35.00 35.00 35.00 
ffilX 
AIN-93G Vitamin 10.00 10.00 10.00 10.00 10.00 10.00 
ffilX 
L-Cystine 3.00 6.00 3.00 3.00 3.00 3.00 
Choline bitartrate 2.50 2.50 2.50 2.50 2.50 2.50 
Tert- 0.014 0.014 0.014 0.014 0.014 0.014 
butylhydroquinone 
L-Methionine 0.00 0.00 0.00 5.00 10.00 20.00 
The diet constituents are given in grams per kg diet 
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Experimental Protocol 
For the study of arteriovenous difference of thiols and other amino acids across 
the intestine, rats were maintained on the above diets for one week prior to 
experimentation. All animals had free access to water and diet. Rats were housed in 
plastic cages, two to a cage, with a stainless steel mesh lid. The room was maintained at 
22 ± 2 °C and 60-70% humidity with a 12-hour light, 12-hour dark cycle which was light 
from 8.00 to 20.00 hours. Initial body weights were recorded. After a 7-day period of ad 
libitum feeding, rats were anaesthetized with sodium pentabarbitol (65 mg.kg- 1, ip) in the 
morning (9.00 hrs). Then, each rat was kept on a dorsal recumbent position on a heating 
pad at around 37°C. The abdomen was opened by a mid-line incision and the gut was 
deflected to the rat's left to expose the hepatic portal vein which was then dissected free 
of surrounding connective tissues. A 2RB perivascular blood flow probe with an L type 
bracket (Transonic® Small Animal Flowmeter T206, Transonic systems Inc., Ithaca, NY, 
USA) was placed around the portal vein as close as possible to the liver. The dead space 
between the portal vein and the flow probe was filled with KY jelly, which improved the 
acoustic coupling. Blood flow was recorded in ml/min, 5 minutes after the probe was 
placed. During this period, blood flow attained a steady value. 
After recording the blood flow of the portal vein, the flow probe was cautiously 
removed. Blunt tearing of the adipose tissues around the vessel exposed the abdominal 
aorta. Blood samples of 1.5 ml from each vessel were collected from the portal vein and 
the abdominal aorta simultaneously, into heparinized syringes. Samples were kept on ice 
for a few minutes. The time from the laparotomy to blood sampling was less than 10 
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minutes. All the rats were in the absorptive state as evidenced by the presence of food in 
the intestine. 
A microcapillary tube was filled with arterial blood to determine the hematocrit 
(Packed Cell Volume, PCV). These tubes were then centrifuged for 15 minutes (Adams 
Autocrit™ Centrifuge, NY, USA) and the PCV was read as a percentage. Blood samples 
collected in heparinized syringes were then transferred to microcentrifuge (Eppendorf) 
tubes and were kept on ice for few minutes. They were centrifuged within 15 minutes of 
sample collection to separate plasma. The immediate removal of blood cells from the 
plasma is important to prevent the release of Hey from erythrocytes into plasma 
(Rasmussen and Moller 2000). Plasma was separated by centrifugation in a clinical 
centrifuge at 3 700 x g for 5 minutes and stored at -20°C until required for HPLC 
analysis of total thiols. However, in the case of samples for the analysis of free thiols, 
plasma was deproteinized and the entire analytical procedure was performed on the same 
day as described below. 
Sample Preparation 
Total and free values of plasma Hey, Cys, Cys-Gly and GSH were measured by a 
method described by Vester and Rasmussen (1991). 
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Total Thiol Assay 
150 J.!l of plasma was mixed with 20 J.!l mixture of 10% (v/v) tri-normal-
butylphosphine (TNB) (Acros Organics, NJ, USA) in N,N dimethyl-formamide. After 
mixing thoroughly, the reduction was allowed to proceed for 30 minutes at 4°C. To each 
sample then added 50 J.!l of the sodium salt of 0.2 mM 8-Aminonaphthalene-1,3,6-
trisulfonic acid (ANTS) ( Molecular Probes, Oregon, USA) prepared in 0.1 M potassium 
borate buffer at pH 9.5 containing 2 mM EDTA. ANTS is used as an internal standard. 
Plasma proteins were precipitated by adding 125 J.!l of 0.6% perchloric acid (PCA) and 
left at room temperature for 10 minutes. They were then centrifuged at 3 700 x g for 5 
minutes after which 1 00 J.!l of the supernatant was transferred into a separate set of 
microcentrifuge tubes. 200 J.!l of 2 M potassium borate at pH 10.5 containing 5 mM 
EDTA and 100 J.!l of the ammonium salt of 7-Fluorobenzofurazan-4-sulfonic acid 
(SBDS) were added. SBDS was used as the derivatization agent and it was prepared by 
dissolving 1 g of SBDS in 1L of 2 M potassium borate at pH 1 0.5. Sample mixtures were 
then incubated at 60 °C for 1 hour in a light-protected water bath. The samples were 
cooled in ice for 5 minutes and centrifuged at 3 700 x g followed by filtering through a 
0.45 J..Lm Millipore filter. At this stage the samples were ready for HPLC analysis and 
kept on ice until they were loaded into the HPLC autosampler. 
Free Thiol Assay 
For this assay it was necessary to precipitate plasma proteins (with bound thiols) 
before the reduction procedure. 150 J.!l of fresh plasma was mixed with 85 J.!l of 0.6 M 
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PCA and kept at room temperature for 10 minutes. It was then centrifuged at 3 700 x g 
for 5 minutes and 150 !J.l of the supernatant was transferred into a new microcentrifuge 
tube. 20 !J.l mixture of 10% (v/v) TNB in N,N dimethyl-formamide was added and mixed 
and the tube was kept at 4° C for 30 minutes. The internal standard, 32 !J.l of 0.2 mM 
ANTS in 0.1 M potassium borate buffer at pH 9.5 with 2 mM EDTA, was then added 
and, finally, 18 !J.l of 0.1 M potassium borate buffer at pH 9.5 containing 2 mM EDTA 
was added. The rest of the procedure was same as for free thiol assay except that 0.6 M 
PCA was not added after ANTS because it had been added at the beginning of the 
procedure. 
HPLC Analysis of Total and Free Thiols 
Plasma free and total thiols were determined by reverse-phase HPLC and 
fluorescence detection of ammonium SBDS thiol adducts, using the method of Vester 
and Rasmussen (1991). Samples prepared as described above, were run through a 
Hypersil ODS 5 !J.m, 150 mm x 4.6 mm column for the separation ofthiols. For both free 
and total thiol assay, 0.2 mM Hey, Cys, Cys-Gly and GSH standards in 0.1 M potassium 
borate buffer, pH 9.5, containing 2 mM EDTA were prepared. 50 !J.l aliquots of these 0.2 
mM standard thiol solution were diluted with I 00 !J.l of 0.1 mM potassium borate buffer, 
pH 9.5, containing 2 mM EDTA to bring the concentrations approximately equal to those 
in the plasma. 
Samples, 20 !J.l, were injected from an autosampler. Elution was brought about by 
means of a gradient of two buffers prepared as described by Vester and Rasmussen 
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(1991). Both buffers were filtered through a 0.45 J..Lm Millipore filter. Two different 
HPLC machines; Shimadzu (Shimadzu Scientific Instruments Inc, USA) and Waters 
(Millipore corporation, Milford, MA, USA) were used during these assays. Both 
machines deployed a similar method in which a linear gradient was run from buffer A to 
buffer B over 12.5 minutes at a flow rate of 1 ml/minute. Then buffer B was run for 2.5 
minutes followed by returning to buffer A for 3 minutes. Finally, buffer A was run for a 
further 2 minutes before the next sample was injected. 
Analysis of Amino Acids 
150 J..Ll of plasma was deproteinized with 25 J..Ll of 10% sulfosalicylic acid (SSA). 
After thorough mixing the samples were kept on ice for 15 minutes. The internal 
standard, 25 J..Ll of 0.25 mM amino ethyl L-cysteine hydrochloride (ABC), was added, 
followed by 162.5 J..Ll of Lithium Citrate at pH 2.2. The samples were then mixed and 
centrifuged at 3 700 x g for 5 minutes. The supernatant, which was about 250 J..Ll in 
volume, was collected and analyzed for amino acids on a Beckman 121 MB amino acid 
analyzer by Mr. Craig Skinner. This system employed Benson D-X, 0.25 Cation Xchange 
Resin and a single-column, three-buffer lithium method as per Beckman 121 MB-TB-0 17 
application notes. A Hewlett Packard Computing Integrator Model 3395A was used for 
quantification. 
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II). Intestinal Homogenate for Enzyme Assay 
Rats, fed normal chow, were anaesthetized with sodium pentabarbitol (65mg.kg-1 ,ip) 
during the fed state. A midline laparotomy was performed to expose the intestinal tract. 
The whole intestine was removed by severing at the proximal duodenal region and at the 
ilea-caecal junction. It was then put in ice-cold 0.9% saline solution. Squeezing gently 
along the intestine, from the proximal to the distal end, emptied the luminal contents. 
Then, using a small piece of rubber tubing attached to a 20 cc syringe, ice-cold normal 
saline was driven through the intestine 3-4 times. Excess saline was swabbed with gauze, 
followed by sectioning the whole length of the intestine into 10 approximately equal 
segments. They were divided into two groups each having alternate segments. Both 
groups were weighed separately and were placed in cold homogenization medium (0.05 
M potassium phosphate buffer at pH 7.0). One group was placed in a centrifuge tube 
containing 4.5 ml of homogenization medium + 0.5 ml of protease inhibitor cocktail and 
the other group was put in 5 ml of homogenization medium alone. The final 
concentration of protease inhibitor in the incubation medium was 5 J..tglml each of 
Phenylmethylsulfonyl fluoride (PMSF), Pepstatin, Chymostatin and Aprotinin and 1 mM 
EDT A. The intestinal tissue segments were cut into small pieces with a pair of scissors, 
while the tissue segments were immersed in the homogenization medium. The tissues 
were homogenized by two 1 0-second bursts with a Polytron (Brinkman instruments, 
Toronto, Canada). Between these two bursts, the tubes were kept on ice. The homogenate 
was then centrifuged at 18 000 x g for 30 minutes at 4 °C. Supernatants were saved and 
kept on ice until used for protein and enzyme assays. 
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Measurement of Protein Content in the Intestinal Homogenate 
Protein was assayed by the Biuret method (Gomall, 1949). The biuret reaction is 
based on the complex formation of cupric ions with proteins. In this reaction, copper 
sulfate is added to a protein solution in strong alkaline solution. A purplish-violet colour 
is produced, resulting from complex formation between the cupric ions and the peptide 
bond. Bovine serum albumin was used as the standard protein solution. 5% deoxycholic 
acid was used to solubilize any membranous material. 
Enzyme Assays of Intestinal Homogenates 
A). Cystathionine-fl-synthase 
The assay was based on a method developed by Mudd et. al. (1965) and modified by 
Taoka et. al. (1998). The assay involved the incorporation of labelled serine into 
cystathionine, which was isolated by anion exchange chromatography. Since the enzyme 
activity was thought to be very low in intestinal tissues, a higher quantity (1 to 9 mg 
protein of intestinal homogenate) was incubated at 3 7 °C for 1 hour with a cocktail 
containing the following ingredients. 125 mM Tris HCl at pH 8.3 and 2.1 mM EDTA 
comprised the cocktail medium which contained the final concentration of 0.146 mM L 
(+) Cystathionine, 41.7 mM DL-Hcy, 0.316 mM SAM, 2.1 mM Propargylglycine and 
0.42 mM PLP. 500 ~1 of the supernatant of the intestinal homogenate was mixed with 
1.33 ml of cocktail. The reaction was initiated by adding 167 ~1 of 300 mM 1-14C serine 
(2 ~Ci/ml) to the incubation medium. 1 ml of ice-cold 15% PCA was added to each tube 
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at the end of a one-hour incubation period to stop reactions. The reaction mixture was 
then centrifuged at 3 700 x g for 5 minutes and the supernatant was saved. 
An aliquot of 1.67 ml of the supernatant was passed through a Bio-Rad AG 50W-
X4 column containing 200-400 mesh hydrogen-form resin. The column was washed in 
the following order; 2 times with 4 ml of water, 6 times with 4 ml of 1 N HCL and 4 
times with 4 ml of water. Then, labelled cystathionine was eluted once with 5 ml of 3 N 
NH40H. Eluates were collected and 1 ml aliquots of the collected eluate were transferred 
into 20 cc scintillation vials. 10 ml of ScintiVerse Xylene solution (Fisher Scientific, NJ, 
USA) was added into each vial. The radioactivity was counted the next day, in a LKG 
WALLAC 1214 RACKBETA liquid scintillation counter. The radioactivity of 10 J.!l of 
300 mM stock 1-14C serine was also determined in 10 ml of ScintiVerse. Each 
determination was corrected by blank values obtained by assays, both with labelled 
substrate-free reaction media and acid denatured homogenates. 
B). S-Adenosylmethionine synthase 
The assay followed a method described by Mudd et. al. (1965). The assay cocktail 
contained 100 mM Tris HCl at pH 7.8, 200 mM KCl, 10 mM MgCh, 1 mM DL-
Dithiothreitol (DTT) and 5 mM A TP. Intestinal homogenates prepared with and without 
protease inhibitors were used as enzyme source. The volume of the intestinal homogenate 
was adjusted so that 60 J.!l volume was equivalent to 0.27 - 1.62 mg protein. The 
intestinal homogenate was incubated with the assay cocktail of 400 J.!l at 3 7 °C for 30 
minutes in a shaking water bath at 60-70 oscillations per minute. The reaction was 
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initiated with the addition of 40 ~1 of 62.5 rnM [1- 14C] methionine (2 ~Ci/m1). After 30 
minutes of incubation, addition of 1.5 ml of ice-cold water followed by immediate 
transfer of all the reaction tubes into an ice water bath stopped the reactions. 
For separation of labelled product from the substrate, Bio-Rad 50W -X4 200-400 
mesh, NH4 + form resin was used. The counter ion of the resin was changed from W to 
~ + by the following procedure. The resin was suspended in de-ionized water for 15 
minutes. Once the resin was settled to the bottom of the beaker, water was discarded. 
The resin was then resuspended in 3 N NH40H twice and washed 3 times with water to 
remove excess ~OH. Finally, the columns were prepared by adding approximately 2 
ml of the resin. 
Once the resin was set in the column, 1.4 ml of stopped sample was added. The resin 
was then washed 5 times with 4 ml of water. Finally, the labelled SAM was eluted with 2, 
3 ml aliquots of 3 N ~OH. The eluate was collected in 20 cc scintillation vials which 
were then mixed with 10 ml of ScintiVerse. Radioactivity was counted on the following 
day in a LKG W ALLAC 1214 RACKBET A liquid scintillation counter. The 
Radioactivity of 10 ~1 of 62.5 mM stock [1- 14C] methionine was also determined in 10 ml 
of ScintiVerse. Each determination was corrected by blank values obtained by assays 
both with labelled substrate-free reaction media and acid denatured homogenates. 
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III). Isolation of Enterocytes 
In preliminary studies, we obtained the best yield of enterocytes from rats that 
weighed between 150 and 250 g. Therefore, the rats used in the isolation of cells were 
approximately 200 g in body weight. They had ingested a chow diet. Enterocytes were 
isolated by a method described by Watford et. al. (1978). Three different modified Krebs-
Henseleit saline solutions were prepared fresh daily; (Saline-1) the medium of Krebs and 
Henseleit (144 mM Na+/6 mM K+/1.3 mM Ca2+/1.2 mM Mg2+/126 mM Cr/1.2 mM 
H2P04-/1.2 mM S0/-125 mM HC03-) [see appendix -IT (Krebs and Henseleit, 1932)] 
from which CaCh was omitted, (Saline-2) the same to which 0.25% (w/v) dialysed serum 
albumin and 5 mM EDTA were added, (Saline-3) the medium ofKrebs-Henseleit (1932) 
with 2.5% (w/v) dialysed serum albumin (Table 2.2). 
Rats were killed by cervical dislocation in order to avoid the use of anaesthetics, 
which may increase the secretion of mucus into the intestinal lumen. Immediately after 
the rats were killed, the abdominal cavity was incised open along the linea alba. The 
small intestine was cut proximally, about 5 em below the pyloric sphincter and distally, 
about 10 em above the colon. After emptying the luminal contents, the intestine was 
flushed 2-3 times from the proximal end of the intestine with ice-cold saline- I gassed 
with 0 2/C02 (19: 1) 
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Table 2.2. The composition of Krebs-Henseleit saline solutions 
Constituents Saline Solution type 
1 2 3 
1). 0.9% Nacl (0.154M) 103 (ml) 103 (ml) 100 (ml) 
2). 1.15% KCl (0.154M) 4 (ml) 4 (ml) 4 (ml) 
3). 1.22% CaCh (O.llOM) 0 0 3 (ml) 
4). 2.11% KH2P04 (0.154M) 1 (ml) 1 (ml) 1 (ml) 
5). 3.8% MgS04.7HzO (0.154M) 1 (ml) 1 (ml) 1 (ml) 
6). 1.3% NaHC03 (0.154M) 21 (ml) 21 (ml) 21 (ml) 
7). Dialyzed serum albumin 0 0.325 (g) 3.25 (g) 
8). EDTA 0 242.2 (mg) 0 
A 40 cc syringe connected with a piece of rubber tubing equipped with a stop-
valve was connected to the proximal end of the intestine. This rubber tubing was used for 
rinsing and filling the lumen with different saline solutions. The distal end of the intestine 
was ligated and the lumen was filled with about 18 ml of gassed saline-2. Once the lumen 
was slightly distended with filled saline-2, the stop-valve was closed and the intestine 
was incubated at 37°C for 15 minutes in a 250 ml conical flask containing 100 ml of 
saline-!. The flask was gassed with 0 2/C02 (19:1) throughout and shaken at 60-70 
oscillations/min. Then, the intestine was opened from the distal end and fluid was drained 
off. The lumen was rinsed two times with about 20 ml of gassed saline-3 injected through 
the rubber tubing attached to the proximal end to remove mucus and loose cells from the 
tips of the villi. The distal end of the intestine was ligated once again and the lumen was 
filled through the proximal end with gassed saline-3 making sure the volume of saline 
injected was sufficient to distend the intestine slightly. The stop-valve was then closed. 
The intestine filled with saline-3, was patted with fingertips for 1 min on an ice-block 
covered by a polythene bag and with three layers of gauze pads on the surface. This was 
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performed to release the enterocytes into the saline-3 medium, which filled the lumen. 
The fluid was drained and collected into polystyrene tubes. These last two steps were 
repeated 4 times and all the drained fluid was collected and centrifuged at 500 x g for 3 
minutes. The supernatant was discarded and the packed cells were washed once with 
approximately 4 volumes of saline-3. Cells were then resuspended in about 4 volumes of 
saline-3. The cells were dispersed in the medium by drawing them up several times into a 
wide-mouthed plastic pipette. 1 ml aliquot of the cell suspension was then transferred to 
microcentrifuge tubes. This was done in order to get an approximately equal number of 
enterocytes in each millilitre because, with time, the enterocytes tend to adhere, forming 
cell clumps. Every time, when the cells were transferred from one container to another as 
well as in the later described incubations, pipette tips that were cut obliquely to provide a 
large orifice were used. 
We also isolated enterocytes in a saline-2 medium containing collagenase (150 
mg/ 200 ml) in an attempt to improve the separation and viability. Apart from the 
addition of collagenase to saline-2, the rest of the procedure was the same as described 
above. 
Dry Weight of Enterocytes 
2 ml of the cell suspension and 2 ml of saline-3 in weighing boats were dried in 
an oven at 60 °C (Fisher isotemp® oven 100 series, Model 106G, USA) for 3 days so as 
to determine the dry weight of the isolated enterocytes. The mean dry weight was 3.1 ± 
0.5 mg/ml. 
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Enterocytes Viability Studies 
Lactate dehydrogenase (LDH) activity was measured to determine the viability of 
isolated enterocytes. Enterocytes were incubated under our experimental conditions for 
0, I5, 30 and 45 minutes. After each incubation, the entire content of cells and the 
incubation medium was centrifuged at 3 700 x g for 5 minutes. The supernatant was 
saved and the cell fraction was resuspended in 2 ml of Krebs Ringers phosphate medium. 
0.9 ml of the cell suspension was taken into a microcentrifuge tube containing O.I ml of 
IO% Triton X-IOO (fmal concentration was I%). We had previously determined that I% 
Triton X -I 00 is sufficient to obtain I 00% lysis of enterocytes. The microcentrifuge tube 
containing enterocytes and Triton X-IOO was kept in ice for I5 minutes. It was then 
frozen in liquid nitrogen followed by thawing back to the room temperature. 20 J..Ll 
volume of supernatant and lysed cell fractions were placed separately in a 2 ml cuvette 
which contained I.8 ml of Krebs Ringer phosphate medium, I 00 J..Ll of NADH (3 mg 
dissolved in I ml of de-ionized water) and 100 J..Ll of pyruvate (3 mg in lml of de-ionized 
water). The change in absorbance at 340 J..Lm over 5 minutes was recorded and LDH 
activity of both the supernatant and cell fraction was calculated using the molar 
extinction coefficient 6.22 X I06 (Bergmeyer I974). The viability of cells was expressed 
as a percentage. 
Transsulfuration Flux of Isolated Enterocytes 
Polyethylene Erlenmeyer flasks of 25 cc were used for all of the incubations with 
enterocytes. This enabled us to avoid glass surfaces that cause enterocytes to adhere. 
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Also, all assays were carried out in triplicate. Incubations were only for 30 minutes 
because the enterocytes had a satisfactory (over 85%) viability for only 45 minutes. The 
incubation medium of 1 ml, comprised the fmal concentration of 1 mM (1- 14C) 
methionine, 1 mM Serine, 1 mM Glutamate, 1 mM Glycine. The volume was made up to 
1 ml with Krebs-Henseleit medium fortified with 10.5 mM Glucose. The final glucose 
concentration in the incubation medium plus enterocytes was 5 mM. The incubation 
medium with all or selected combination of the above mentioned substrates was added to 
Erlenmeyer flasks. The flasks were gassed with 19:1 0 2/C02 for 30 seconds and stopped 
until the enterocytes were added. 
In the second reaction of transsulfuration, a.-ketobutyrate is produced; the 
carboxyl carbon of this substance derives from the number 1 carbon of methionine. [ l-
14C] a.-ketobutyrate is converted to propionyl CoA by pyruvate dehydrogenase. As a 
result, the carboxyl carbon is liberated as 14C02. However, some [ 1-14C] a.-ketobutyrate 
may remain un-metabolized. The label of this fraction can be cleaved chemically as 
14C02 by adding 30% (w/v) H20 2. The total production of 14C02 by both of these 
methods will be a measure of transsulfuration flux. 14C02 was trapped in plastic centre 
wells containing NCS-II tissue solubilizer (Amersham International, Oakville, Ontario, 
Canada). 
All flasks were incubated at 37°C for 30 minutes in a shaking water bath at 60 
oscillations per minute. The transsulfuration reactions were started with the addition of 1 
ml enterocytes. The flasks had been gassed for 15 seconds before the cells were added. A 
further 15 second gassing was carried out after enterocytes were added. Flasks were then 
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sealed with rubber septae equipped with plastic centre wells, containing a ribbed piece of 
blotting paper. The collection of 14C02 for the measurement of transsulfuration flux was 
as described by Stead.et. al. (2000) 
Transsulfuration Inhibition Studies 
In a separate series of experiments, the same incubations were carried out in the 
presence and absence of 2 mM propargylglycine and 0.5 mM a-cyanocinnamate, which 
are inhibitors of cystathionine-y-lyase and the mitochondrial transport of a-ketobutyrate, 
respectively. 
Production I Removal of Thiols in Isolated Enterocytes 
Enterocytes also were incubated in the presence and absence of 1 mM methionine 
and 1 mM Hey. After 30 minutes of incubation, the reaction was stopped by adding 0.3 
ml of 30% (w/v) perchloric acid. The production/removal of Hey, Cys and GSH were 
measured by the reverse phase HPLC method (Vester and Rasmussen, 1991 ). 
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DATA ANALYSIS AND PRESENTATION 
Results are expressed as means ± SD (number of rats used). Significant difference 
between arterial and portal concentration (A-V differences) of thiols and other amino 
acids were determined by paired t-test, as appropriate. Body weight gain, portal blood 
flow differences in hematocrit values between diet groups and differences in thiol 
concentration in arterial and portal venous blood in different diet groups were compared 
by one way ANOV A and Newman-Keuls Multiple Comparison Test. The Student t test 
was used to differentiate the significance of free and bound fractions of thiols. Statistical 
analyses were conducted using GraphPad Prism 3.02 32 Bit Executable. A P value less 
than 0.05 was taken as statistically significant. 
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RESULTS AND DISCUSSION 
CHAPTER3 
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INTRODUCTION 
The portal-drained viscera play a fundamental role in the supply of dietary 
nutrients to the rest of the body. These organs consume a disproportionately higher 
quantity of dietary available nutrients compared with their relative tissue mass. There are 
numerous experimental data on the fluxes of nutrients and other substrates across the 
portal-drained viscera of pigs. However, according to our knowledge, there is only one 
publication on the A-V balance of SAA across this organ bed in rats (Garcia and 
Stipanuk 1992). These authors did not measure blood-flow. Therefore, no study has been 
carried out to determine the fluxes of all major thiols. Therefore, we decided to study the 
net balances and fluxes of SAA across the portal-drained viscera in rats fed diets with 
different amounts of casein, cystine and methionine. 
WEIGHT GAIN OF RATS DURING THE DIETARY PROTOCOL 
The initial weight of the rats was 246.6 ± 29.7 g. The mean weight gain of rats 
during the 7 -day period on diets is reported in Table 3 .1. Rats fed the control diet and the 
0.6% cystine-enriched diet grew at an average rate of about 10 g/day. Rats fed a 2% 
methionine diet, showed no weight gain during the 7 -day dietary period. The high protein 
and 1% methionine-supplemented groups had a slightly, but significantly lower (P < 
0.05) weight gain when compared with the controls as well as the rats on the 0.6% 
cystine-supplemented diets. No significant difference in the weight gain was observed 
between rats on the high protein diet, the 0.5% and 1% methionine-supplemented diets. 
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Table 3.1. Effects of diet on weight gain of rats fed for a 7-day period 
Diet group Mean weight gain g/day 
20% Casein+ 0.3% cystine 10.5 ± 1.7a 
20% Casein + 0. 6% cystine 10.7 ±2.6a 
60% Casein+ 0.3% cystine 8.5 ± 1.8c 
20% Casein+ 0.3% cystine+ 0.5% methionine 9.4 ± 1.9bc 
20% Casein+ 0.3% cystine+ 1% methionine 7.9 ± 1.0°c 
20% Casein+ 0.3% cystine+ 2% methionine 0.3 ± 0.9e 
Values are means ± SD for n = 6-18 rats. Values without a common letter superscript are 
significantly different (P < 0.05) by ANOVA and Newman-Keuls Multiple Comparison 
Test. 
Portal Blood Flow and Hematocrit Values 
Table 3.2 reports the mean values for the portal blood flow and hematocrit of rats 
m each diet group. No significant difference was observed for portal blood flow. 
However, the hematocrit or PCV value varied significantly between diet groups. Except 
0.6% cystine-supplemented group, all other diet groups showed a significantly elevated 
PCV than the control group. 
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Table 3.2. Effect of diet on Portal Blood Flow (PBF) and Packed Cell Volume (PCV; 
hematocrit) of rats after a 7-day period on each diet 
Diet group Mean PBF ml/min Mean PCV 0/o 
20o/o Casein+ 0.3% cystine 23.9±5.0 40.5±2.2a 
20% Casein + 0. 6% cystine 23.4±4.8 41.3±2.0aoc 
60% Casein+ 0.3% cystine 24.0±3.0 42.4±1.8cd 
20% Casein+ 0.3o/o cystine+ 0.5% methionine 23.0±3.9 43.3±1.20de 
20% Casein+ 0.3% cystine+ 1% methionine 23.7±7.6 45.3±2.5e 
Values are means± SD for n = 6-18 rats. Within each column, values without a common 
letter superscript are significantly different (P < 0.05) by ANOVA and Newman-Keuls 
Multiple Comparison Test. 
A-V Differences for Thiols across the Portal Drained Viscera 
For reasons, which will be addressed in the discussion, we measured the arterio-
venous (A-V) differences of the thiols in plasma rather than in whole blood. Cys, Hey, 
Cys-Gly and GSH were measured. The portal vein contains blood draining the stomach, 
intestines, spleen and pancreas. Therefore, the arteriovenous difference in this study 
represents the absorptive and metabolic activity of all the portal-drained viscera, not 
necessarily by the gastrointestinal tract. The concentration of thiols in the portal vein is 
the balance of a number of effects such as the products of SAA metabolism within these 
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organs, inputs from diet, turnover of epithelial cells, secretions and products of bacterial 
actions. 
Arterial and portal venous concentrations of each thiol across the portal-drained 
viscera of rats, fed different diets, were analysed. A-V differences were calculated by 
subtracting the concentration of a compound in the plasma of portal venous sample from 
that of arterial sample drawn simultaneously from the same rat. The results were 
expressed as output(-) or uptake(+) by the portal-drained viscera (Table 3.3). The rates 
of thiol uptake and output were expressed using portal blood flow and the percentage of 
plasma volume in whole blood (Table 3.4). 
As shown in Figure 3.1, a net output of tCys into the portal vein was observed in 
rats fed the 0.6% cystine-supplemented diet, the 60% casein diet and the 0.5% 
methionine-supplemented diet. 
Table 3.4 shows the net flux of the different thiols across the portal-drained 
viscera. There was significant output of total Cys in the portal-drained viscera in rats fed 
the 0.6% cystine-supplemented diet and 60% casein diet. 
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Table. 3.3. The arterial and portal venous concentrations & A-V difference of 
plasma total thiols across the portal-drained viscera of rats fed 6 different diets for 7 
days. 
Diet C .rsteine (J..Lmoles/L) Ilomocysteine(J..Lmoles/L) 
A v A-V A v A-V 
DI 277±36.0 311±28.0 -34.0±34.0 11.0±2.0 11.7±1.8 -0.4±1.2 
Dz 262±29.0 294±44.0 -31.0±47.0* 10.0±2.0 9.8±2.1 -0.08±0.7 
D3 298±37.0 343±45.0 -45.0±31.0* 12.0±2.0 12.9±2.6 -0.54±0.8 
D4 282±57.0 299±66.0 -17.0±20.0* 35.0±24.0 34.5±23.9 0.78±3.2 
Ds 233±29.0 250±51.0 -16.0±30.0 122±53.0 118±49.0 3.0±12.5 
D6 295±20.0 293±24.0 1.5±19.0 296±139 267±130 29.3±20.4* 
Diet Cysteinylglycine (J..Lmoles/L) Glutathione (J..Lmoles/L) 
A v A-V A v A-V 
DI 0.64±0.19 0.71±0.17 -0.06±0.1 25.9±5.0 21.9±4.7 3.8±2.2* 
Dz 0.68±0.2 0.73±0.2 -0.04±0.1 23.8±2.0 19.9±2.6 3.8±1.1 * 
D3 0.80±0.2 0.81±0.1 -0.02±0.1 22.2±3.0 20.6±3.0 1.6±2.4 
D4 0.78±0.1 0.80±0.2 -0.02±0.04 26.3±4.0 21.9±4.1 4.4±3.2* 
Ds 0.72±0.1 0.71±0.1 0.00±0.1 21.1±3.0 17.0±3.6 4.1±1.5* 
D6 NIM N/M NIM 27.5±6.0 23.0±5.6 4.4±3.8* 
The values are means± SD for 6-14 rats. * Significantly different from zero (P < 0.05) 
by paired t test. The results were expressed as output/export (-) or uptake/removal ( +) by 
the portal-drained viscera. D 1, 20% casein + 0.3% cystine diet; D2 , 20% casein + 0.6% 
cystine diet; D3, 60% casein + 0.3% cystine diet; D4, 20% casein + 0.3% cystine +0.5% 
methionine diet; D5, 20o/o casein+ 0.3% cystine+ 1% methionine diet; D6, 20% casein+ 
0.3% cystine+ 2% methionine diet. N/M, not measured. 
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Figure 3.1. Total Cys levels in arterial & portal plasma & A-V difference across the 
portal-drained viscera for rats on different diets for 7 days. 
Values are for means± SD for n = 6-14 rats. * A-V difference is significantly different 
from zero (P < 0.05) by the paired t test. Values without common letter superscripts are 
significantly different for arterial tCys concentrations between diet groups (P < 0.05) by 
ANOV A and Newman-Keuls Multiple Comparison Test. D 1, 20% casein + 0.3% cystine 
diet; D 2, 20% casein + 0.6% cystine diet; D 3, 60% casein+ 0.3% cystine diet; D 4 , 20% 
casein + 0.3% cystine +0.5% methionine diet; D5, 20% casein + 0.3% cystine + 1% 
methionine diet; D6, 20% casein+ 0.3% cystine+ 2% methionine diet. 
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Table 3.4. Net fluxes of thiols across the portal-drained viscera in rats fed different 
diets for 7 days. 
Diet Net Flux (J.1mol/min/100g) 
tCys tHey tGSH tCys-Gly 
D1 -0.104±0.124 -0.001±0.007 0.023±0.012* 0 
D2 -0.131±0.204* -0.000±0.004 0.017± 0.006* 0 
D3 -0.219±0.079* -0. 004±0. 002 0.006±0.012 0 
D4 -0.071±0.100 0.001± 0.010 0.020± 0.013* 0 
Ds -0.047±0.135 0.020± 0.055 0.019± 0.012* 0 
Values are means ± SD for determinations on 6-12 rats. A positive sign indicates an 
uptake or removal by the organ bed, and a negative sign indicates a release or export by 
the organ bed. * A-V difference is significantly different from zero (P < 0.05) by the 
paired t test. Values were analyzed for statistically significant difference by ANOV A and 
Newman-Keuls Multiple Comparison Test. No differences were found. D1, 20% casein+ 
0.3% cystine diet; D2, 20% casein+ 0.6% cystine diet; D3, 60% casein+ 0.3% cystine 
diet; D 4, 20% casein + 0.3% cystine +0.5% methionine diet; D 5 , 20% casein + 0.3% 
cystine + 1% methionine diet. 
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In contrast to the output of Cys, we observed a net intestinal uptake of tHey from 
the arterial blood in rats fed a 2% methionine-supplemented diet. The tHey 
concentrations in the arterial, portal blood and A-V differences are illustrated in Figure 
3.2. The tHey A-V difference in the 2% methionine fed rats was 29.3 ± 20.4 J.!mol!L. 
However, we did not measure the blood flow in this diet group. Both arterial and portal 
tHey concentrations are significantly higher in rats fed methionine-supplemented diets 
than in the rest of the diet groups. The arterial tHey concentration in this group was 
296.4± 139.5 J.!mol!L. It was approximately 25-fold higher than the control value. The 
0.5% methionine-supplemented group had about an 11-fold increase in arterial tHey 
concentration compared to the control value (Figure 3 .2). 
When the A-V differences for tHey in all the diet groups were plotted as a 
function of arterial tHey concentration, a positive and significant relationship was 
observed (Figure 3.3). 
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Figure 3.2. Total Hey levels in arterial & portal plasma & A-V difference across the 
portal-drained viscera for rats on different diets for 7 days. 
Values are for means ± SD for n = 6-14 rats. * A-V difference is significantly different 
from zero (P < 0.05) by the paired t test. Values without common letter superscript are 
significantly different for arterial tHey concentrations between diet groups (P < 0.05) by 
ANOV A and Newman-Keuls Multiple Comparison Test. D 1, 20% casein+ 0.3% cystine 
diet; D 2, 20% casein + 0.6% cystine diet; D 3, 60% casein+ 0.3% cystine diet; D4, 20% 
casein + 0.3% cystine +0.5% methionine diet; D 5, 20% casein + 0.3% cystine + 1% 
methionine diet; D 6, 20% casein+ 0.3% cystine+ 2% methionine diet. 
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Figure 3.3. A-V of tHey across the portal-drained viscera as a function of arterial 
tHey for rats in all the diet groups 
n = 68 rats. Linear regression analysis showed an r2 = 0.6462 and P = <0.0001 
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As illustrated in Figure 3.4, the portal-drained viscera removed substantial amounts of 
plasma GSH from arterial blood in all diet groups except the 60% casein group. The rate 
of arterial GSH uptake was approximately 0.02 J.!mol/min/lOOg for the diet groups that 
showed a net uptake (Table 3.4). 
We also measured the balance of Cys-Gly across the portal drained viscera as an 
indicator of the fate of GSH in the organ bed. Cys-Gly is an intermediate product of GSH 
catabolism. As shown in Figure 3.5, there was no significant A-V difference across the 
portal-drained viscera in any of the diet groups. Moreover, no diet group showed a 
significant difference in their arterial and portal concentrations of Cys-Gly. However, we 
did not measure Cys-Gly balances in rats fed a 2% methionine diet. 
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Figure 3.4. Total GSH levels in arterial & portal plasma & A-V difference across the 
portal-drained viscera for rats on different diets for 7 days. 
Values are for means± SD for n = 6-14 rats. * A-V difference is significantly different 
from zero (P < 0.05) by the paired t test. Values without common letter superscript are 
significantly different for arterial tGSH concentrations between diet groups (P < 0.05) by 
ANOVA and Newman-Keuls Multiple Comparison Test. D 1, 20% casein+ 0.3% cystine 
diet; D2, 20% casein + 0.6% cystine diet; D3, 60% casein+ 0.3o/o cystine diet; D4, 20% 
casein + 0.3% cystine +0.5% methionine diet; D 5, 20% casein + 0.3% cystine + 1% 
methionine diet; D6, 20% casein+ 0.3o/o cystine+ 2% methionine diet. 
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Figure 3.5. Total Cys-Gly levels in arterial & portal plasma & A-V difference across 
the portal-drained viscera for rats on different diets for 7 days. 
Values are for means ± SD for n = 6-12 rats. Values were analyzed for statistically 
significant difference by ANOVA and Newman-Keuls Multiple Comparison Test. No 
differences were found. D 1, 20% casein + 0.3% cystine diet; D2, 20% casein + 0.6% 
cystine diet; D 3, 60% casein+ 0.3% cystine diet; D4, 20% casein+ 0.3% cystine +0.5% 
methionine diet; D 5, 20% casein+ 0.3% cystine+ 1% methionine diet; D6, 20% casein+ 
0.3% cystine+ 2% methionine diet. 
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Plasma Free and Protein-Bound Thiols across the Portal-Drained Viscera 
The free and protein-bound fractions of all 4 thiols were measured so as to 
determine, in particular, the chemical form by which dietary Cys is added to the portal 
plasma (Table 3.5). All rats in this experiment were fed the 60% casein diet for 7 days 
since this diet group was responsible for the highest output of tCys into the portal blood 
(Table 3.4). The data in Table 3.5 confirm our earlier observation of an appreciable 
appearance of cysteine in the portal plasma. 64% of plasma Cys was in the free form. 
Almost all the Cys exported to the portal vein was in the non-protein bound form (Figure 
3.6). The percentage of free Hey and GSH in the arterial blood was 44% and 71%, 
respectively. Cys-Gly in the arterial blood was absolutely in the free form. 
Table 3.5. Plasma total and non-protein bound concentration of thiols across the 
portal drained viscera in rats fed 60°/o casein diet for 7 days. 
Thiol Total (Jlmoles/L) Free (Jlmoles/L) 
A v A-V A v A-V 
Cys 309.2±30.2 354.0±44.2 -44.7±33.0 199.5±27.9 248.5±30.4 -49.0±25.4 
Hey 14.3±2.3 14.9±2.4 -0.6±0.8 6.3±1.5 7.9±1.6 -1.7±0.8 
Cys-Gly 0.7±0.2 0.8±0.1 -0.03±0.05 0.9±0.2 1.03±0.1 - 0.2±0.1 
GSH 20.8±2.3 18.9±2.1 1.9±1.5 15.0±2.2 13.1±1.4 1.9±1.8 
Values are means± SD for n = 12 rats. 
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Figure 3.6. Plasma total and non-protein bound Cys in the arterial and portal blood 
and A-V differences for rats fed on 60o/o casein diet for 7 days 
Values are means ± SD for n = 12 rats. A-V values with asterisks are significantly 
different from zero (P < 0.05) by paired t test. 
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A-V Differences for Amino Acids across the Portal Drained Viscera 
In addition to thiols, we measured the A-V differences and the fluxes of 
methionine and other amino acids (See the appendix). A significant portal output of 
methionine was observed only in rats fed 0.5% methionine supplemented diets. The A-V 
difference was -6.99 ± 4.31 ~mol/L. A striking finding was the observation of taurine 
production by the portal-drained viscera when animals were supplemented with 
methionine but not with cystine. 
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DISCUSSION 
A-V differences are often measured in whole blood samples rather than in the 
plasma. Whole blood could give a complete picture independent of certain constraints 
such as the movement of compounds between plasma and cells during transit through the 
organ bed. However, in our case, use of whole blood values would result in very high 
baseline concentrations in contrast to our ability to detect small changes in A-V 
differences. For instance, the bulk of GSH in whole blood is sequestered in the red blood 
cells. These cells are impermeable to plasma GSH (Mortenson et. a/.1956). Conversely, 
Cys is present primarily in the plasma and its concentration in the blood cells is relatively 
very low (Levy and Berkin 1971). Therefore, plasma concentrations were used to 
determine the A-V values for all thiols in this study. 
The observation of tCys output (Figure 3.1) into the portal blood does not agree 
with the observation of Stoll et. a/. in piglets ( 1998) who found no additional cystine in 
the portal vein. Stoll et. a/. concluded that dietary Cys was quantitatively metabolized 
within the intestine. Our data do, however, agree with that of Garcia and Stipanuk (1992) 
who also found a net output of tCys into the portal vein. At ftrst, we thought that these 
differences might be accounted for by analytical methodology. We and Garcia and 
Stipanuk used a reduction step in the assay and, therefore, measured total Cys. Stoll et. a/. 
only measured non-protein bound cyste(i)ne. For this reason, we postulated that dietary 
Cys appears in the portal blood in the albumin-bound form and that this form is, 
therefore, metabolically active (Prathapasinghe et. a/. 2004). To test this assumption, we 
measured the arteriovenous difference of total and non-protein bound Cys across the 
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intestine. Since 60% casein + 0.3% cystine diet gave a highest output of tCys, we fed a 
group of rats with the same diet in this assay. 
Almost all the Cys exported into the portal vein was in the free form. However, 
we have not defined the relative importance of the different free forms. The simplest 
hypothesis would be that Cys added to the portal vein is in the form of cysteine and or 
cystine. However, Cys readily forms mixed disulfides with other thiols. Therefore, it is 
certainly possible that some of the absorbed Cys is in the mixed disulfide form. It is well 
known that Cys-Hcy occurs in plasma. In addition, Dahm and Jones (1994) have shown 
that vascularly perfused rat intestine cleared 45% of oxidized GSH (GSSG) in a single 
pass. This resulted in an output of the mixed disulfide of cysteine and GSH (CysSG). 
Therefore, it is possible that some of the absorbed Cys occurs in the form of this mixed 
disulfide. However, additional experimentation is required to delineate the specific forms 
in which Cys is added to portal blood. 
The 60% casein fed rats exported the highest amount of tCys into the portal blood 
(Figure 3.1). This may be due to the higher level of Cys that was available in this diet. 
Each 100 g of casein provided 3.2 g of methionine equivalents (2.8 g methionine+ 0.4 g 
Cys). Thus, the Cys available through casein in this diet group was 0.24%. Given that 1 g 
of methionine, if completely metabolized to Cys, is equivalent to 0.8 g of Cys, the total 
availability of Cys in the 60% casein diet group goes even higher (Stipanuk et. al. 2002). 
Therefore, 60% casein group may have had the highest supply of Cys among the rest of 
the diet groups. 
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We report, for the first time, that tHey, at very high concentrations in the arterial 
blood, is removed by the portal drained viscera. Although this increased plasma tHey 
concentration is not observable in any normal dietary situation, human patients with 
severe hyperhomocysteinemia do have extremely high levels of plasma tHey. Therefore, 
it can be suggested that the intestine may play a role in lowering plasma tHey under 
certain pathological situations in which the plasma tHey level is extremely high. This 
may be important in patients with diseases such as inflammatory bowel disease, Crohn's 
disease, and short bowel syndrome. All these patients show significantly elevated plasma 
tHey level which is not necessarily related to low vitamin B cofactors that are required 
for methionine remethylation and transsulfuration (Romagnuolo et. a/. 2001; 
Koutroubakis et. a/. 2000). Perhaps the increased Hey is a result of the bowel diseases. 
GSH is needed as a reducing agent to reduce many toxic oxidizing agents. The 
intestine, in particular, is exposed to severe oxidative stress, especially during the fed 
state. GSH is the preferred reducing agent to counteract those oxidative stresses in this 
organ (Harward et. a/.1994). GSH is used in the small intestine to detoxify peroxidized 
lipids in the mucosal epithelium and to detoxify reactive electrophils in mucus and 
mucosal epithelium (Aw and Williams 1992). Bile is thought to be the source ofGSH for 
the functions within the intestinal lumen (Aw et. a/.1992; Aw and Williams 1992). In 
addition, GSH is also released to the lumen from the intestinal epithelium (Wien and van 
Campen 1991). The uptake of GSH by the portal-drained organ bed observed in this 
thesis, is consistent with previous findings in rats (Garcia and Stipanuk 1992). However, 
the quantity of GSH taken up by the rats in our experiment is somewhat higher than that 
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of Garcia and Stipanuk's. Even though the intestinal tissues have the enzymatic 
capability to synthesize GSH and the rate of its synthesis in the mucosa is very high 
(Jahoor et. a!. 1995), a further uptake from arterial source may well explain the extent of 
oxidative stress that this organ faces during the absorptive state in particular (Jahoor et. 
a!. 1996). 
We also measured the A-V difference of Cys-Gly in an attempt to study 
the fate of the GSH that was taken up by the organ bed. Cys-Gly is a metabolic product 
of GSSG/GSH degradation produced by y-GT (Grafstrom et. a!. 1980). Consistent with 
previous research findings, we also did not observe any intake or output of Cys-Gly 
across the portal drained viscera (Dahm and John 1994). 
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CHAPTER4 
INTRODUCTION 
From the metabolic prospective, intestinal cells are unique. First, the nutrients for 
the mucosal epithelial cells of the small intestine can be derived from both the luminal 
and arterial sides. Second, enterocytes are specialized for the unidirectional movement of 
dietary absorbed nutrients from the lumen to the portal vein through the basal lamina. 
Third, enterocytes display substantial metabolic plasticity and a metabolic favouritism 
towards certain substrates. With regard to sulfur amino acids, the small intestine 
consumes 30% of dietary available methionine though the gastrointestinal system 
represents only about 7% of the whole body mass (Reeds et. al. 1996). The small 
intestine is one of the very few organs that is equipped with all of the enzymes required 
for the transmethylation, remethylation and transsulfuration pathways. A few studies 
have been carried out on sulfur-containing amino acid (especially Cys) metabolism in 
enterocytes. However, no data are available on the fate of exogenous methionine in these 
cells. Since methionine is an essential amino acid as well as the source for all the other 
sulfur-containing amino acids in the body, we decided to study the metabolic fate of 
exogenous methionine in isolated rat enterocytes, together with enzyme activities in 
intestinal tissue homogenates. 
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ATTEMPTS TO IDENTIFY A CELL ISOLATION MEDIUM THAT WOULD 
IMPROVE ENTEROCYTES VIABILITY 
Initial experiments were conducted to determine a suitable cell isolation medium. 
We used two different cell isolation media as described in the Materials and Methods; 
one with saline-2 with added collagenase and the other with saline-2 alone. Table 4.1 
reports the viability of cells isolated with these media. Viability was assessed for different 
times of incubation. Enterocytes isolated without collagenase gave better viability 
compared with those isolated with collagenase. Therefore, we did not employ 
collagenase for enterocytes isolation and we restricted our incubation time to no more 
than 30 minutes. 
Table 4.1. Viability percentages of isolated enterocytes by two different cell isolation 
media 
Method Incubation time (min) and viability {0/o) 
0 15 30 45 
No collagenase 97,98 87, 88 79,82 45,51 
Collagenase 87, 88 83,84 67, 76 53, 61 
n = 2 rats. 
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DETERMINATION OF A SUITABLE INCUBATION MEDIUM FOR 
TRANSSULFURATION FLUX STUDIES 
Isolated enterocytes were suspended in Krebs-Henseleit-3 medium (see Materials 
and Methods). This medium contained 2.5% bovine serum albumin. For the studies of 
transsulfuration flux, we incubated enterocytes in a medium devoid of exogenous sulfur-
containing amino acids other than the labelled methionine and the other amino acids such 
as serine, glutamate and glycine that are involved in transsulfuration and in the synthesis 
of GSH. In preliminary studies we found that enterocytes incubated in either Krebs-
Henseleit-3 or normal Krebs-Henseleit medium, had approximately the same viability (as 
judged by LDH leakage) for 45 minutes of incubation (Figure 4.1 ). Therefore, the normal 
Krebs-Henseleit medium was used as our incubation medium in all the enterocyte 
experiments. 
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Figure 4.1. Leakage of LDH from enterocytes incubated in Krebs-Henseleit-3 
medium vs. normal Krebs-Henseleit. Both media contained 1 mM methionine, 1 
mM serine, 1 mM glutamate and 1 mM glycine 
KH-3 SN, supernatant from the cells incubated in Krebs-Henseleit-3 medium; KH normal 
SN, supernatant from the cells incubated in Krebs-Henseleit medium; K.H-3 total, LDH 
activity remaining in enterocytes incubated in Krebs-Henseleit-3 medium and lysed by 
Triton X-100; KH normal total, LDH activity remaining in enterocytes incubated in 
Krebs-Henseleit medium and lysed by Triton X-100 
79 
TRANSSULFURATION FLUX IN ISOLATED RAT ENTEROCYTES 
Transsulfuration of [ 1-14C] methionine was determined by the total 
production of 14C02 from enterocytes with 1 mM [1- 14C] methionine, 1 mM serine, 1 
mM glutamate and 1 mM glycine. When enterocytes are incubated with L-[1- 14C] 
methionine some 14C02 is produced as a result of the mitochondrial metabolism of cx.-
ketobutyrate to propionyl Co-A (Figure 4.2). This fraction of 14C02 is readily collected 
and counted. However, some cx.-ketobutyrate may remain unmetabolized. Label in 
unmetabolized ex.-[ 1-14C] keto butyrate can be released with H20 2 . Such 14C02, released 
from cx.-ketobutyrate, must also be included in measures of flux through the 
transsulfuration pathway. 
Table 4.2 reports the values for transsulfuration flux in isolated 
enterocytes that were incubated in the presence of [1- 14C] methionine, serine, glutamate 
and glycine. Serine was supplied as it is a substrate for cystathionine f3-synthase and 
glycine and glutamate are necessary for GSH synthesis. The production of 14C02 from 1 
mM [ 1-14C] methionine was unaffected by the presence of 1 mM each of serine, 
glutamate or glycine. No statistically significant difference was observed in the rate of 
transsulfuration by isolated enterocytes in the presence and absence of these amino acids. 
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Figure 4.2. The metabolic fate of [1-14C] of methionine in the transsulfuration 
pathway. 
Propargylglycine, an irreversible inhibitor of cystathionine-y-lyase; a-cyanocinnamate, an 
inhibitor of mitochondrial transporter of a-keto butyrate. 
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Table 4.2. Transsulfuration flux in isolated enterocytes. 
Contents of the incubation medium Total 14C02 production (nmollmg/30min) 
(1 mM) 
Met* 1.7 ± 0.8 
Met*+Ser 1.4 ± 0.9 
Met*+Glu+Gly 1.7 ± 1.3 
Met*+Glu 1.9 ± 0.6 
Met*+Gly 1.5 ± 0.9 
Values are means ± SD for n = 5 experiments. Values were analyzed for statistically 
significant differences by ANOV A and Newman-Keuls Multiple Comparison Test. No 
difference was found in the rate of transsulfuration between incubation media with 
different amino acids added. Met*, [ 1- 14C] methionine; Ser, serine; Glu, glutamate; Gly, 
glycine. 
The relative contributions of 14C02 and a-ketobutyrate to the total transsulfuration 
flux reported in Table 4.2 are illustrated in Figure 4.3. The accumulation of a-
ketobutyrate contributed most to the total rate of transsulfuration. 
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Figure 4.3. Flux of [1-14C] methionine through the transsulfuration pathway in 
isolated rat enterocytes: production of 14C02 and [1-14C] a-ketobutyrate 
Values are means ± SD for n = 5 experiments. Values were analyzed for statistically 
significant differences by ANOV A and Newman-Keuls Multiple Comparison Test. No 
difference was found in the rate of transsulfuration between incubation media with 
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different amino acids added. Met*, [ 1-14C] methionine; Ser, serine; Glu, glutamate; Gly, 
glycine. 
Transsulfuration 1s not the sole metabolic pathway by which 14C02 can be 
released from [1- 14C] of methionine. There are three other possible ways: 
decarboxylation of SAM in the polyamine synthetic pathway, transamination followed by 
oxidation of the keto acid of methionine, and the cleavage of SAM between carbon atom 
3 and 4. To determine whether the 14C02 produced was actually a product of the 
transsulfuration pathway, propargylglycine, an irreversible inhibitor of cystathionine-y-
lyase, was included in the incubations (see Figure 4.2). As shown in the Figure 4.4, 
blocking cystathionine-y-lyase did not result in any significant reduction in total 14C02 
production from enterocytes. However, the production of the 14C02 component but not of 
a-ketobutyrate was significantly lowered. Further, when enterocytes were incubated with 
a-cyanocinnamate, an inhibitor of the mitochondrial a-keto acid transporter, there was no 
decline in 14C02 production. These results contrast with those of Stead et. a!. (2000) with 
hepatocytes. These investigators found that propargylglycine decreased the total 
transsulfuration flux and that a-cyanocinnamate decreased the 14C02 component without 
affecting the total flux. 
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Figure 4.4. Flux of [1-14C] methionine through the transsulfuration pathway in 
isolated rat enterocytes: Effects of propargylglycine and a-cyanocinnamate 
Values are means ± SD for n = 3 experiments. Values were analyzed for statistically 
significant difference by ANOVA and Newman-Keuls Multiple Comparison Test. There 
was no difference of total 14C02 production in the presence of propargylglycine or a-
cyanocinnamate. Met*, [1- 14C] methionine; 2 mM Prop., Propargylglycine; a-Cyan. , a-
Cyanocinnamate; methanol, the solvent in which the inhibitors were dissolved. 
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PRODUCTIONIREMOV AL OF TIDOLS BY INCUBATED ENTEROCYTES 
To further examine the contribution of the transsulfuration pathway in the 
methionine metabolism of isolated enterocytes, we also examined the production and 
removal of Hey, Cys and GSH (Table 4.3). As illustrated in Figure 4.5, when enterocytes 
were incubated in the presence of I mM methionine, there was a production of both Hey 
and Cys whereas GSH was removed from the cells when compared with their initial 
concentrations. However, the values were extremely low. In addition, there was no 
difference between the results with no added amino acids. 
Table 4.3 Concentration of thiols in the isolated enterocytes before and after 
incubation in the presence and absence of 1 mM methionine. 
Incubation Hey (nmoles/mg dry Cys (nmoles/mg dry GSH (nmoles/mg dry 
medium weight) weight) weight) 
0 time 30min 0 time 30min 0 time 30min 
I mM each of 0 0.48±0.I4 5.I±2.8 I7.9±6.9 I2.5±6.I 6.8±6.6 
Met+Ser+Glu+Gly 
I mM each of 0 0.48±0.I6 5.I±2.8 20.7±5.4 I2.5±6.I 6.5±6.6 
Ser+Glu+Gly 
Values are means± SD for n =3 experiments. Values were analyzed by Student's t test. 
There was no difference in the concentration of thiols after 30 minutes of incubation, in 
the presence or absence of methionine. 
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Figure 4.5 Production/Removal of Hcy,Cys & GSH by the enterocytes incubated in 
the presence and absence of 1 mM methionine, Serine, Glutamate and Glycine. 
Values are means ± SD for n =3 experiments. Values were analyzed by Student's t test. 
There was no difference in the production/removal of thiols in the presence or absence of 
methionine. Met, methionine; Ser, serine; Glu, glutamate; Gly, glycine. With methionine, 
1 mM each of Met+Ser+Glu+Gly; Without methionine, 1 mM each of Ser+Glu+Gly 
87 
We then examined whether Hey is metabolized via the transsulfuration pathway 
m isolated rat enterocytes. As shown in Figure 4.6, the production of Cys was 
significantly increased from 10.8 nmoles/mg dry enterocytes/30 min to 41.8 nmoles/mg 
dry enterocytes/30 min, when enterocytes were incubated with added 1 mM Hey. 
However, the removal of Hey (70.3 nmoles/mg dry enterocytes/30 min) was not 
stoichiometrically equal to the production of Cys. Relatively low amounts of GSH were 
removed with or without Hey in the incubation medium. 
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Figure 4.6. Production/Removal of Hcy,Cys &GSH by the enterocytes incubated in 
the presence and absence of 1 mM each of Homocysteine, Serine, Glutamate and 
Glycine. 
Values are means for n = 2 experiment. Hey, homocysteine; Ser, serine; Glu, glutamate; 
Gly, glycine. With Hey, 1 mM each of Hcy+Ser+Glu+Gly; Without Hey, 1 mM each of 
Ser+Glu+Gly 
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THE ACTIVITY OF ENZYMES OF METIDONINE METABOLISM IN 
INTESTINAL HOMOGENATES 
In a separate set of experiments, we evaluated the activities of two key enzymes 
of the transmethylation and remethylation pathways in the rat small intestine. Tissue 
homogenates of rat small intestine were prepared either with or without a cocktail of 
protease inhibitors in the homogenization medium. The protease inhibitor cocktail 
contained 5 ~g/ml each of Phenylmethylsulfonyl fluoride (PMSF), Pepstatin, 
Chymostatin and Aprotinin and 1 mM EDTA. The activity of CBS in the intestinal 
homogenate is illustrated in Figure 4.6. The mean activity of CBS was found to be 6.13 ± 
5.40 nmoles/min/g intestine and 5.87± 6.86 nmoles/min/g intestine of homogenate in the 
presence and absence of protease inhibitor cocktail, respectively. The values were not 
significantly different from each other. Interestingly, we found no measurable enzyme 
activity for SAM synthase in the tissue homogenate both in the presence and absence of 
protease inhibitors. However, we must note that Finkelstein et al. (1971) found 2.2 
nmoles/mg protein/60 min of SAM synthase activity in intestinal homogenate. 
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Figure 4.7. The tissue activity of cystathionine-f3-synthase in the rat small intestinal 
homogenate . 
Values are means± SD for n = 3 experiments. Results were analyzed by Student's t test. 
No differences were found between the two groups. PI, Protease Inhibitor cocktail. 
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DISCUSSION 
We found that methionine is appreciably metabolized by enterocytes. The total 
14C02 production is comparable to rates found in isolated hepatocytes. In rat hepatocytes, 
the total production of 14C02 from 1 rnM L-[1- 14C] methionine was reported to be 2.79 
nmols/mg dry weightlh (Stead et. al. 2000). In the present work, enterocytes showed a 
similar rate; however, the production of the 14C02 component was quite low, compared 
with the [ 1-14C] a- ketobutyrate. Conversely, in rat hepatocytes, the major contributor to 
the total 14C02 production was the production of 14C02 rather than [1- 14C] a-
ketobutyrate. Therefore, it may be suggested that a- ketobutyrate is not as readily utilized 
for mitochondrial energy generation in enterocytes, as it is in hepatocytes. In addition, the 
lack of effect of added 1 rnM serine on the rate of 14C02 or [1- 14C] a- ketobutyrate 
production provides another striking difference between enterocytes and hepatocytes. 
This difference is further emphasized by the finding that the irreversible inhibitor of 
CGL, propargylglycine, did not decrease the production of [1- 14C] a-ketobutyrate and the 
resulting total production of 14C02 • The simplest explanation for this is that 
propargylglycine may not be an effective inhibitor of CGL in enterocytes possibly 
because of reduced permeability to the cell. Otherwise, it may be argued that [1- 14C] a-
ketobutyrate produced from [1- 14C] methionine was not from the transsulfuration 
pathway. The deamination of SAM in the polyamine synthetic pathway, the cleavage of 
SAM into homoserine and subsequent catabolism into a-ketobutyrate and the 
transamination of methionine into its keto acid, keto-methionine, are the other possible 
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ways that uninterrupted production of [ 1-14C] keto acid could occur in the presence of 
propargylglycine. 
Experiments reported in Figure 4.5 and Figure 4.6 show a considerable 
production of Cys from Hey but not from methionine. These results may suggest that 
SAM synthase and transmethylation may be a significant limitation in the intestinal 
catabolism of methionine. The data in figure 4.6 give a strong indication that exogenous 
Hey is metabolized into Cys. Thus, the transsulfuration pathway from Hey seems to be 
functioning in the enterocytes. The presence of CBS activity in intestinal homogenates 
(Figure 4.7) further supports the possible occurrence of the transsulfuration pathway in 
the isolated enterocytes. Furthermore, we found no activity of SAM synthase activity in 
the intestinal homogenate. Mudd et. a/. (1965) also found very low activity in the 
intestine. This is consistent with a very low rate of methionine utilization by enterocytes. 
The observations that propargylglycine did not inhibit the production of [l- 14C] a-
ketobutyrate (Figure 4.4) and no SAM synthase activity was found in intestinal 
homogenate may rule out that the transsulfuration, the polyamine synthesis and the SAM 
cleavage pathways were responsible for the production of [l- 14C] a-ketobutyrate from [l-
14C] methionine in enterocytes. Thus, the only remaining known pathway that is left 
behind is the transamination of [ l- 14C] methionine. We must consider that, in 
enterocytes, the 14C02 release by H20 2 does not come from a-ketobutyrate. H20 2 is 
known to decarboxylate all a-keto acids. The transaminated product of methionine, a-
keto-y-methiolbutyrate carries the labelled carbon at the carboxyl terminus. Chemical 
treatment with H20 2 may have liberated it as 14C02 . Benevenga and Eagen (1983) have 
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shown the presence of the amino-accepting keto acid, a-keto-y-methiolbutyrate, in the 
intestinal homogenate of rats. Therefore, it should be considered, in future studies, that 
enterocyte methionine metabolism may occur, in part, via pathways other than 
transsulfuration. 
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CHAPTERS 
SUMMARY 
Summary 
1. Cys is exported to the portal vein in rats fed diets supplemented with high casein, 
cystine or a moderate level (0.5%) of methionine. 
2. The exported fraction of Cys is in the non-protein bound form. 
3. The portal-drained viscera remove Hey from the arterial plasma when the arterial 
tHey concentration is very high. 
4. GSH is removed from arterial plasma in all the dietary conditions except in 60% 
casein fed rats. 
5. Enterocytes metabolize methionine at an appreciable rate. However, this may not 
occur via transmethylation. However, the transsulfuration pathway is active in 
isolated enterocytes as evidenced by the catabolism of Hey to Cys in these cells. 
6. The CGL inhibitor, propargylglycine, did not inhibit the "transsulfuration flux" of 
[ l- 14C] methionine by enterocytes. It is possible that this inhibition is not effective 
in enterocytes, possibly because of reduced cellular permeability. Alternatively, it 
should be considered that 14C02 released by H20 2 may not be in a-ketobutyrate. It 
could, conceivably, arise from the a-keto acid of methionine, a-keto-y-
methythiolbutyrate. This would imply that the transamination pathway must be 
quite active in enterocytes. 
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APPENDICES 
Table A-1 Plasma arterial, portal venous and A-V differences for amino acids in 
rats fed 20°/o casein+ 0.3o/o cystine containing diet for 7 days. 
20%, Casein+ 0.3°/o cystine diet group (f.lmol/L) 
Amino acid A v A-V 
Phosphoserine 6.1±1.9 8.9±2.4 -2.8±2.2* 
Taurine 119.4±21.6 124.8±25.3 -5.3±14.7 
Aspartic acid 9.7±4.6 11.8±6.3 -2.1±4.8 
Hydroxyproline 28.4±5.5 25.1±4.0 3.3±3.9 
I Threonine I 29o.o±49.5 321.1±78.3 -31.1±40.5 
Serine 149.1±46.9 200.7±112.1 -51.6±69.1 
Asparagine 47.9±14.8 61.1±15.3 -13.2±16.0 
Glutamic acid 49.6±17.1 63.2±28.7 -13.5± 12.5* 
Glutamine 329.7±67.6 305.6±102.5 24.0±46.2 
Proline 316.3±78.8 400.8±167.5 -84.5±91.6 
Glycine 60.0±18.9 89.2±8.2 -29.1±20.3* 
Alanine 382.4±101.7 589.9±238.0 -207.5±144.7* 
Citrulline 44.1±8.5 65.6±17.9 -21.4±11.4* 
a-amino-n-butyric acid 6.3±2.2 5.7±2.6 0.67±1.9 
Valine 194.7±62.5 232.5±106.9 -37.8±46.3 
Methionine 46.3±15.6 59.5±32.3 -13.1±17.2 
Isoleucine 78.3±29.5 103.0±60.8 -24.6±32.2 
leucine 125.2±63.4 165.8±115.6 -40.6±52.9 
Tyrosine 98.2±36.8 114.8±56.6 -16.5±23.7 
Phenylalanine 43.8±15.5 60.6±36.6 -16.7±21.4 
Tryptophan 46.1±25.1 70.5±25.5 -24.4±46.3 
Ethanolamine 6.3±3.3 5.5±2.8 0.75±4.3 
Ornithine 35.0±9.2 36.3±5.6 -1.3±5.6 
Lysine 421.5±116.3 473.3±188.2 -51.7±88.3 
Histidine 37.4±7.0 49.1±25.1 -11.6±18.8 
Arginine 54.6±24.2 67.7±38.7 -13.1±16.5 
Values are means± SD for n = 6 rats. * Significantly different from zero (P < 0.05) by 
paired t test. 
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Table A-2 Plasma arterial, portal venous and A-V differences for amino acids in 
rats fed 20% casein + 0.6o/o cystine containing diet for 7 days. 
20o/o Casein+ 0.6°/o cystine diet group (J.lmol/L) 
Amino acid A v A-V 
Phosphoserine 4.9±0.6 6.6±1.1 -1.7±1.2* 
Taurine 152.5±23.5 166.9±30.6 -14.4±28.2 
Aspartic acid 7.2±2.2 10.9±3.2 -3.6±1.8* 
Hydroxyproline 27.4±5.2 26.2±5.5 1.1±4.4 
Threonine 250.2±63.4 252.5±52.6 -2.3±35.3 
Serine 129.3±30.2 145.6±27.9 -16.2±15.2* 
Asparagine 39.2±10.0 55.7±11.2 -16.4±7.5* 
Glutamic acid 43.8±9.8 52.2±9.8 -8.3±6.2* 
Glutamine 280.5±59.9 235.8±43.3 44.7±31.9* 
Proline 266.9±81.7 304.3±65.0 -37.3±38.0 
Glycine 56.4±13.4 91.6±21.5 -35.1±15.2* 
Alanine 331.4±94.1 445.4±88.2 -114.1±54.4* 
Citrulline 43.6±8.8 59.5±10.4 -15.8±8.8* 
a-amino-n-butyric acid 5.9±2.1 4.9±1.3 0.94±2.0 
Valine 173.2±53.3 179.9±46.0 -6.7±21.5 
Methionine 40.4±10.4 45.0±9.5 -4.5±4.8 
Isoleucine 70.8±25.9 79.5±24.6 -8.6±8.0* 
leucine 110.2±42.1 126.1±40.1 -15.9±9.8 
Tyrosine 84.9±14.9 90.5±13.2 -5.5±8.0 
Phenylalanine 37.7±11.3 45.8±11.5 -8.1±3.6* 
Tryptophan 59.4±15.1 60.0±12.6 -0.6±12.4 
Ethanolamine 4.7±0.36 5.4±1.5 -0.7±1.4 
Ornithine 34.8±14.2 35.3±12.0 -0.56±5.8 
Lysine 328.4±78.8 343.5±66.4 -15.1±44.9 
Histidine 34.7±8.5 39.0±9.1 -4.2±5.3 
Arginine 53.1±15.5 60.3±13.7 -7.1±8.1 
Values are means ± SD for n = 6 rats. * Significantly different from zero (P < 0.05) by 
paired t test. 
99 
Table A-3 Plasma arterial, portal venous and A-V differences for amino acids in 
rats fed 60% casein+ 0.3% cystine containing diet for 7 days. 
60o/o Casein+ 0.3o/o cystine diet group (J.lmol/L) 
Amino acid A v A-V 
Phosphoserine 5.4±1.1 7.7±1.2 -2.3±2.3 
Taurine 80.2±25.8 78.6±23.2 1.5±23.9 
Asj>_artic acid 6.5±1.3 12.8±3.3 -6.3±3.7* 
Hydroxyproline 13.1±7.6 12.0±5.3 1.1±7.7 
Threonine 133.5±34.8 158.5±49.6 -25.0±43.3 
Serine 83.4±22.4 119.7±34.3 -36.2±33.6 
Asparagine 32.1±8.5 61.9±19.5 -29.8±17.1 * 
Glutamic acid 45.0±9.1 66.4±17.1 -21.4±14.7* 
Glutamine 238.4±55.0 209.9±46.2 28.5±75.1 
Proline 331.5±110.7 445.1±158.6 -113.6±145.9 
Glycine 43.4±13.3 100.3±28.0 -56.8±27.6* 
Alanine 295.9±89.1 451.4±112.7 -15 5. 6± 116.1 * 
Citrulline 36.6±8.7 47.2±11.2 -10.6±13.0 
a-amino-n-butyric acid 11.3±3.8 9.6±3.2 1.6±4.2 
Valine 383.3±76.5 379.9±116.9 3.3±83.4 
Methionine 35.0±7.6 40.8±8.8 -5.7±11.1 
Isoleucine 119.7±31.7 135.6±46.8 -15.8±27.3 
leucine 191.6±49.0 211.3±70.1 -19.6±41.6 
Tyrosine 57.9±13.0 66.0±16.9 -8.1±16.3 
Phenylalanine 35.9±6.9 50.1±13.1 -14.1±13.0* 
Tryptophan 50.6±9.1 51.8±11.3 -1.1±15.9 
Ethanolamine 3.2±1.4 4.8±1.5 -1.6±1.7 
Ornithine 31.3±11.9 29.6±9.2 1.7±10.0 
Lysine 361.5±66.1 366.7±90.8 -5.2±90.8 
Histidine 30.3±6.2 37.6±9.5 -7.2±9.3 
Arginine 59.0±12.2 62.6±16.9 -3.6±17.1 
Values are means ± SD for n = 6 rats. * Significantly different from zero (P < 0.05) by 
paired t test. 
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Table A-4 Plasma arterial, portal venous and A-V differences for amino acids in 
rats fed 20o/o casein+ 0.3°/o cystine+ O.So/o methionine containing diet for 7 days. 
20%, Casein+ 0.3o/o cystine+ 0.5°/o Met diet 2roup umol/L) 
Amino acid A v A-V 
Phosphoserine 4.6±0.4 6.8±1.1 -2.2±1.0* 
Taurine 124.5±29.5 150.0±44.4 -25.5±21.8* 
Aspartic acid 6.3±1.4 8.7±2.5 -2.3±1.2* 
Hydroxyproline 19.2±5.7 23.0±4.3 -3.7±3.5* 
Threonine 175.8±38.8 198.3±45.6 -22.4±12.5* 
Serine 89.3±13.5 106.7±17.6 -17.2±6.6* 
Asparagine 28.1±4.2 41.3±5.6 -13.2±2.9* 
Glutamic acid 39.5±11.1 48.6±13.4 -9.1±3.0* 
Glutamine 219.8±44.9 195.9±38.8 23.8±20.0* 
Proline 186.8±43.3 232.3±55.4 -45.5±16.5* 
Glycine 39.1±7.1 69.6±16.7 -30.4±9.8* 
Alanine 274.7±57.9 397.5±75.3 -122.8±28.1 * 
Citrulline 31.9±10.1 51.5±15.5 -19.5±6.7* 
a-amino-n-butyric acid 6.0±3.6 8.2±2.3 -2.2±3.7* 
Valine 140.0±34.6 157.3±40.6 -17.3±10.6 
Methionine 47.8±9.1 54.8±11.5 -6.9±4.3* 
Isoleucine 54.4±15.0 66.0±16.6 -11.6±3.0* 
leucine 85.3±24.1 102.7±28.7 -17.3±6.6* 
Tyrosine 57.4±12.8 65.1±13.3 -7.6±4.6* 
Phenylalanine 29.5±8.1 36.8±10.7 -7.2±3.4* 
Tryptophan 48.6±15.4 56.8±15.7 -8.1±4.9* 
Ethanolamine 2.5±2.2 4.7±2.2 -2.1±0.8* 
Ornithine 33.9±12.1 41.3±16.9 -7.4±6.8* 
Lysine 280.2±60.3 317.1±67.3 -36.9±19.3* 
Histidine 27.0±6.1 33.0±7.8 -6.0±2.5* 
Arginine 37.9±13.3 46.0±17.9 -8.0±6.0* 
Values are means ± SD for n = 6 rats. * Significantly different from zero (P < 0.05) by 
paired t test. 
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Table A-5 Plasma arterial, portal venous and A-V differences for amino acids in 
rats fed 20o/o casein+ 0.3°/o cystine+ 1 o/o methionine containing diet for 7 days. 
20o/o Casein+ 0.3o/o cystine+ 1 o/o Met diet group (Jtmol/L) 
Amino acid A v A-V 
Phosphoserine 5.3±1.0 9.7±3.0 -4.4±2.8* 
Taurine 154.9±38.9 179.4±41.8 -24.5±17.2* 
Aspartic acid 6.2±1.8 8.7±2.3 -2.5±0.7* 
Hydroxyproline 24.2±6.4 24.6±5.0 -0.3±3.2 
Threonine 221.7±46.9 223.7±43.8 -1.9±23.5 
Serine 97.2±18.4 97.7±15.6 -0.4±14.0 
Asparagine 25.0±5.1 32.0±7.2 -7.0±4.6* 
Glutamic acid 42.9±11.4 48.0±11.0 -5.1±4.4* 
Glutamine 212.5±49.7 176.4±27.0 36.0±30.2* 
Proline 163.4±31.5 181.5±34.0 -18.1±19.7 
Glycine 43.9±8.6 71.6±12.2 -27.6±5.8* 
Alanine 265.6±55.9 345.1±57.3 -79.5±31.7* 
Citrulline 38.2±12.2 53.3±17.7 -15.1±7.2* 
a-amino-n-butyric acid 12.6±3.5 13.4±4.7 -0.7±2.4 
Valine 116.6±37.4 116.9±33.0 -0.3±14.0 
Methionine 267.1±180.3 275.0±190.1 -7.8±33.4 
Isoleucine 49.7±18.6 50.7±16.0 -0.9±6.8 
leucine 77.6±29.4 78.8±25.2 -1.2±11.0 
Tyrosine 59.1±21.1 59.9±17.0 -0.8±7.9 
Phenylalanine 32.5±9.3 34.3±8.2 -1.8±4.3 
Tryptophan 44.1±14.7 47.2±15.5 -3.0±3.8 
Ethanolamine 4.1±2.3 4.7±1.2 -0.6±3.0 
Ornithine 32.9±15.7 40.8±17.0 -7.8±13.0 
Lysine 305.7±61.8 312.1±39.3 -6.3±32.6 
Histidine 33.4±10.0 35.4±7.8 -1.9±5.1 
Arginine 42.7±8.0 44.1±8.6 -1.3±6.2 
Values are means± SD for n = 6 rats. * Significantly different from zero (P < 0.05) by 
paired t test. 
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Table A-6 Amino acid fluxes across the portal-drained viscera of rats fed different 
diets for 7 days. 
A-V across the Portal Drained Viscera in JJ,moUmin/lOOg body weight Mean± SD 
Amino acid Dt D2 DJ D4 Ds 
Phosphoserine -0.011±0.006 -0.007±0.005 -0.01 0±0.0 10 -0.009±0.004 -0.020±0.013 
Taurine -0.024±0.070 -0.063±0.113 0.014±0.123 -0.110±0.104 -0.116±0.098 
Aspartic acid -0.008±0.0178 -0.016±0.008 -0.023±0.0188 -0.009±0.005 -0.0 11±0.006 
Hydroxyproline 0.0148±0.018 0.0038±0.020 0.008± 0.039 -0.016±0.016 -0.003±0.014 
Threonine -0.139±0.168 -0.005±0.143 -0.11 0±0.222 -0.097±0.061 -0.031±0.098 
Serine -0.207±0.219 -0.070±0.061 -0.167±0.168 -0.073±0.033 -0.015±0.055 
Asparagine -0.072±0.077 -0.073±0.030 -0.138±0.083b -0.055±0.015 -0.034±0.029b 
Glutamic acid -0.059±0.041 -0.036±0.024 -0.097±0.069c -0.037±0.014 -0.027±0.030c 
Glutamine 0.1325±0.187 0.2081±0.142 0.146± 0.394 0.093± 0.08 0.129± 0.08 
Proline -0.354±0.300 -0.162±0.149 -0.503±0.720 -0.194±0.082 -0.098±0.1 08 
Glycine -0.152±0.108 -0.154±0.054 -0.262±0.127 -0.128±0.046 -0.124±0.063 
Alanine -0.915±0.454 -0.505±0.205 -0.705±0.556 -0.520±0.154 -0.376±0.257 
Citrulline -0.098±0.040 -0.071±0.033 -0.046±0.063 -0.082±0.033 -0.067±0.047 
a-ammo-n- 0.003± 0.009 0.0043±0.010 0.009± 0.022 -0.01 0±0.0 18 -0.005±0.009 
butyric acid 
Valine -0.15 6±0 .161 -0.028±0.089 0.038± 0.437 -0.074±0.050 -0.015±0.057 
Methionine -0.053±0.054 -0.020±0.018 -0.025±0.056 -0.029±0.020 -0.069±0.163 
Isoleucine -0.099±0.1 05 -0.038±0.031 -0.068±0.139 -0.049±0.017 -0.011±0.027 
leucine -0.162±0.167 -0.069±0.035 -0.083±0.213 -0.073±0.031 -0.016±0.047 
Tyrosine -0.067±0.084 -0.024±0.031 -0.035±0.083 -0.032±0.022 -0.011±0.030 
Phenylalanine -0.068±0.069 -0.035±0.011 -0.065±0.065 -0.031±0.016 -0.012±0.019 
Tryptophan -0.087±0.149 -0.001±0.047 -0.002±0.082 -0.035±0.024 -0.017±0.019 
Ethanolamine 0.0051±0.019 -0.002±0.005 -0.007±0.007 -0.009±0.004 -0.004±0.014 
Ornithine -0.009±0.028 -0.002±0.023 0.01 06±0.051 -0.031±0.029 -0.037±0.055 
Lysine -0.213±0.328 -0.062±0.179 -0.004±0.476 -0.159±0.093 -0.058±0.134 
Histidine -0.045±0.067 -0.018±0.022 -0.032±0.046 -0.026±0.012 -0.013±0.023 
Arginine -0.052±0.057 -0.029±0.029 -0.016±0.088 -0.034±0.025 -0.011±0.028 
Values are means ± SD for n = 6 rats in each group. Values with similar letter 
superscripts are significantly different (P < 0.05) from each other by one way ANOV A, 
and Newman-Keuls Multiple Comparison Test. 
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